var title_f30_19_31024="LV endomyocardial fibrosis";
var content_f30_19_31024=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endomyocardial fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    On two-dimensional echocardiography (panel A), typical apical obliteration (0) by a fibrocalcific process renders the left ventricular (LV) cavity very small. The net effect is a severe restrictive cardiomypathy with left atrial (LA) enlargement. The M-mode echocardiogram (panel B) shows the characteristic echoes arising from the apical mass and the very poor mitral valve (MV) opening motion associated with depressed stroke volume.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Harry Acquatella, del Hospital Universitario de Caracas, Venezuela.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_19_31024=[""].join("\n");
var outline_f30_19_31024=null;
var title_f30_19_31025="Positioning for puncture of olecranon fossa";
var content_f30_19_31025=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F61544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F61544&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Positioning for ultrasound-guided puncture of olecranon fossa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient and needle positioning for puncture of olecranon fossa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Introductory Guide to Musculoskeletal Ultrasound for the Rheumatologist, Second Edition. ISBN 978-90-313-9206-3; Bohn Stafleu van Loghum, Houten 2012. Copyright &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_19_31025=[""].join("\n");
var outline_f30_19_31025=null;
var title_f30_19_31026="Azelastine (ophthalmic): Pediatric drug information";
var content_f30_19_31026=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Azelastine (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?16/47/17139?source=see_link\">",
"    see \"Azelastine (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/17/38164?source=see_link\">",
"    see \"Azelastine (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7977087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Optivar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10584896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiallergic, Ophthalmic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10584926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/47/17139?source=see_link\">",
"      see \"Azelastine (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: Children &ge;3 years and Adults: Instill 1 drop into each affected eye twice daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7977140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic, as hydrochloride [drops]: 0.05% (6 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Optivar&reg;: 0.05% (6 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7977090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10585098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply finger pressure to lacrimal sac during and for 1-2 minutes after instillation to decrease risk of systemic effects; avoid contact of bottle tip with skin or eye.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10584900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of itching of the eye associated with allergic conjunctivitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7977085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Optivar&reg; may be confused with Optiray&reg;, Optive&trade;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Optivar [U.S.] may be confused with Opthavir brand name for acyclovir [Mexico]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F7977104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Bitter taste",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision (temporary), conjunctivitis, eye pain, transient burning/stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, dyspnea, pharyngitis, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10584901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to azelastine or any component",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10584902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic solution not for use in contact lens-related irritation; preservative in ophthalmic solution may be absorbed by soft contact lenses; wait at least 10 minutes after instillation before inserting soft contact lenses",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9770046\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7977095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7977096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have shown toxic effects to the fetus at maternally toxic doses.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10584925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells in the blood vessels",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10585099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/17/38164?source=see_link\">",
"      see \"Azelastine (ophthalmic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15941 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-403C6C9E42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_19_31026=[""].join("\n");
var outline_f30_19_31026=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977087\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584896\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584926\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977140\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977090\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10585098\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584900\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977085\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977104\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584901\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584902\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298803\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770046\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977095\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7977096\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10584925\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10585099\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15941\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15941|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?7/53/8022?source=related_link\">",
"      Azelastine (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/54/12132?source=related_link\">",
"      Azelastine (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/20/5445?source=related_link\">",
"      Azelastine (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/47/17139?source=related_link\">",
"      Azelastine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/17/38164?source=related_link\">",
"      Azelastine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_19_31027="MRI showing osteochondral injury talus";
var content_f30_19_31027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55291&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI showing osteochondral injury of the talus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 418px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This MRI scan&nbsp;demonstrates an osteochondral injury of the talus (white arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Patrice Eiff, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_19_31027=[""].join("\n");
var outline_f30_19_31027=null;
var title_f30_19_31028="Normal right hand x-ray";
var content_f30_19_31028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Plain radiograph of a normal right hand (AP, lateral, and oblique)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 584px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The radiograph of the right hand in the AP (A), lateral (B), and oblique (C) projections are normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_19_31028=[""].join("\n");
var outline_f30_19_31028=null;
var title_f30_19_31029="Daunorubicin: Pediatric drug information";
var content_f30_19_31029=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Daunorubicin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"    see \"Daunorubicin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/50/22309?source=see_link\">",
"    see \"Daunorubicin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cerubidine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F157118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cerubidine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Anthracycline",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Antibiotic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"      see \"Daunorubicin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. (refer to individual protocols):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;2 years or &lt;0.5 m",
"     <sup>",
"      2",
"     </sup>",
"     : Dosage should be calculated on the basis of body weight rather than body surface area: 1 mg/kg or per protocol with frequency dependent on regimen employed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ALL combination therapy: Remission induction: 25-45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 8 of cycle, or 30-45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days every 3-4 weeks, or 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every week for 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AML combination therapy: Induction: I.V. continuous infusion: 30-60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day on days 1-3 of cycle, or 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 4 days every 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 30-60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3-5 days, repeat dose in 3-4 weeks; total cumulative dose should not exceed 400-600 mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AML: Single agent induction: 60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days; repeat every 3-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AML: Combination therapy induction: 45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 3 days of the first course of induction therapy; subsequent courses: Every day for 2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ALL: Combination therapy: Remission induction: 45 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1, 2, and 3 of induction course",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic or renal impairment:",
"     </b>",
"     Reduce dose by 25% in patients with serum bilirubin of 1.2-3 mg/dL; reduce dose by 50% in patients with serum bilirubin and/or creatinine &gt;3 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F157095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cerubidine&reg;: 20 mg [contains mannitol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 5 mg/mL (4 mL, 10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F157080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral: Drug is very irritating, do not inject I.M. or SubQ; administer IVP diluting the reconstituted dose in 10-15 mL NS and administering over 2-3 minutes into the tubing of a rapidly infusing I.V. solution of D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS; daunorubicin has also been diluted in 100 mL of D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS and infused over 30-45 minutes or as a continuous 24-hour infusion",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F157166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS, SWFI.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Dexamethasone, fluorouracil, heparin, sodium bicarbonate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amifostine, anidulafungin, caspofungin, etoposide phosphate, filgrastim, gemcitabine, granisetron, melphalan, methotrexate, ondansetron, sodium bicarbonate, teniposide, thiotepa, vinorelbine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, aztreonam, cefepime, fludarabine, piperacillin/tazobactam.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1046907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from light; reconstituted solution is stable for 48 hours when refrigerated and 24 hours at room temperature; a color change from red to blue/purple indicates decomposition of the drug; unstable in solutions with a pH &gt;8; incompatible with heparin, sodium bicarbonate, fluorouracil, and dexamethasone",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In combination with other agents in the treatment of leukemias (ALL, AML)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F157169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       DAUNOrubicin may be confused with DACTINomycin, DOXOrubicin, DOXOrubicin liposomal, epirubicin, IDArubicin, valrubicin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Conventional formulation (Cerubidine&reg;, DAUNOrubicin hydrochloride) may be confused with the liposomal formulation (DaunoXome&reg;)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F157165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Transient ECG abnormalities (supraventricular tachycardia, S-T wave changes, atrial or ventricular extrasystoles); generally asymptomatic and self-limiting. CHF, dose related, may be delayed for 7-8 years after treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia (reversible); discoloration of saliva, sweat, or tears, radiation recall, skin &ldquo;flare&rdquo; at injection site",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperuricemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, diarrhea, GI ulceration, diarrhea, mild nausea or vomiting, stomatitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Discoloration of urine (red)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Myelosuppression (onset: 7 days; nadir: 10-14 days; recovery: 21-28 days), primarily leukopenia; thrombocytopenia and anemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Anaphylactoid reaction, arrhythmia, bilirubin increased, cardiomyopathy, hepatitis, infertility; local (cellulitis, pain, thrombophlebitis at injection site); MI, myocarditis, neutropenic typhlitis, pericarditis, secondary leukemia, skin rash, sterility, systemic hypersensitivity (including urticaria, pruritus, angioedema, dysphagia, dyspnea); transaminases increased",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to daunorubicin or any component; CHF, left ventricular ejection fraction &lt;30% to 40%, or arrhythmias; pre-existing bone marrow suppression",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduce dosage in patients with hepatic, or renal impairment",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     , or in patients with biliary impairment. Should be administered under the supervision of an experienced cancer chemotherapy physician",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     ; I.V. use only; severe local tissue necrosis will result if extravasation occurs",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . May cause severe myelosuppression, dose-limiting, primarily leukopenia and neutropenia",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; irreversible myocardial toxicity may occur as total dosage approaches 550 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     in adults, 400 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     in patients receiving chest radiation, 300 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     in children &ge;2 years of age, or 10 mg/kg in children &lt;2 years",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; this may occur during therapy or several months after therapy; total cumulative dose should take into account previous or concomitant treatment with cardiotoxic agents or irradiation of chest; infants and children may be more susceptible to anthracycline-induced cardiotoxicity than adults; monitor left ventricular (LV) function (baseline and periodic) with ECHO or MUGA scan; monitor ECG. Secondary leukemias may occur when used with combination chemotherapy or radiation therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9837877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F157089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bevacizumab: May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: May diminish the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic). Antineoplastic Agents (Anthracycline, Systemic) may decrease the serum concentration of Cardiac Glycosides. The effects of liposomal formulations may be unique from those of the free drug, as liposomal formulation have unique drug disposition and toxicity profiles, and liposomes themselves may alter digoxin absorption/distribution.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Taxane Derivatives: May enhance the adverse/toxic effect of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may increase the serum concentration of Antineoplastic Agents (Anthracycline, Systemic). Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the cardiotoxic effect of Antineoplastic Agents (Anthracycline, Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F157091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F157103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause fetal harm when administered to a pregnant woman. Animal studies have shown an increased incidence of fetal abnormalities.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count, serum bilirubin, serum uric acid, liver function test, ECG, ventricular ejection fraction, renal function test; patency of I.V. line",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibition of DNA and RNA synthesis by intercalating between DNA base pairs, uncoiling of the helix, and by steric obstruction; not cell cycle-specific for the S-phase of cell division; may cause free radical damage to DNA",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely distributed in tissues such as spleen, heart, kidneys, liver, and lungs; does not cross the blood-brain barrier; crosses the placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: To daunorubicinol (active)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, terminal: 14-18.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Daunorubicinol, active metabolite: 26.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 40% of dose excreted in bile; &sim;14% to 23% excreted in urine as metabolite and unchanged drug",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1046909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/50/22309?source=see_link\">",
"      see \"Daunorubicin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Transient red-orange discoloration of urine can occur for up to 48 hours after a dose; notify physician if fever, sore throat, bleeding, bruising, chills, signs of infection, abdominal pain, blood in stools, excessive fatigue, yellowing of eyes or skin, or difficulty breathing occurs",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1046920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Myelosuppressive effects:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     WBC: Severe",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Platelets: Severe",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset (days): 7",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nadir (days): 10-14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Recovery (days): 21-28",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Crom WR, Glynn-Barnhart AM, Rodman JH, et al, &ldquo;Pharmacokinetics of Anticancer Drugs in Children,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1987, 12(3):168-213.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/19/31029/abstract-text/3555940/pubmed\" id=\"3555940\" target=\"_blank\">",
"        3555940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13207 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-3DC0084E0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_19_31029=[""].join("\n");
var outline_f30_19_31029=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708684\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157117\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157118\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046912\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046905\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157095\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157080\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046916\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157166\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046907\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046915\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157169\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157165\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046919\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046904\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046903\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837877\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157089\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157091\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157103\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046911\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046902\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046918\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046909\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046920\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13207\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13207|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=related_link\">",
"      Daunorubicin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/50/22309?source=related_link\">",
"      Daunorubicin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_19_31030="Chronic abdominal wall pain";
var content_f30_19_31030=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic abdominal wall pain",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/19/31030/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/19/31030/contributors\">",
"     George W Meyer, MD, FACP, MACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/19/31030/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/19/31030/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/19/31030/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/19/31030/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/19/31030/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic pain emanating from the abdominal wall is frequently unrecognized or confused with visceral pain, often leading to extensive diagnostic testing before an accurate diagnosis is achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/1-7\">",
"     1-7",
"    </a>",
"    ]. Once considered, the diagnosis can often be established with a history and physical examination. Treatment with a local anesthetic agent is effective for most patients, and can further help to confirm the diagnosis.",
"   </p>",
"   <p>",
"    This topic review will focus on the diagnosis and treatment of abdominal wall pain. An approach to patients presenting with abdominal pain is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=see_link\">",
"     \"Differential diagnosis of abdominal pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact prevalence of abdominal wall pain is unknown. Abdominal wall pain has been diagnosed in 10 to 90 percent of patients with abdominal pain of unknown cause in various series based upon the patient cohort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/5\">",
"     5",
"    </a>",
"    ]. In one study, 5 to 10 percent of patients referred to specialist practices in gastroenterology had a diagnosis of chronic abdominal wall pain. In another study, 20 percent of patients admitted to a surgical department for abdominal pain had abdominal wall pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women appear to be four times more likely to have chronic abdominal wall pain than men. The peak incidence is between the ages of 30 to 50 years, although cases have been reported in children and the elderly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;While many conditions can cause chronic pain in the abdomen (eg, radicular pain radiating from T7 to T12 lesions [such as are caused by Herpes zoster infection] or referred pain from abdominal or thoracic sources), the term \"chronic abdominal wall pain\" usually refers to anterior cutaneous nerve entrapment syndrome (ACNES), one of the most common causes of this condition. The following discussion will focus on this condition, while the other causes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=see_link\">",
"     \"Differential diagnosis of abdominal pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been suggested that the neurovascular bundles of T7 to T11 may be the source of the pain in the abdominal wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/2\">",
"     2",
"    </a>",
"    ]. The cutaneous branches of sensory nerves arising from T7 to T12 make a 90-degree angle as they progress anteriorly through the posterior rectus sheath, passing through a fibrous ring within the lateral border of the rectus abdominis medial to the linea semilunaris. Having reached the overlying aponeurosis, the nerves divide again at 90-degree angles beneath the skin. Normally, fat in the neurovascular bundle permits the nerve to slide unimpeded within the fibrous ring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/3\">",
"     3",
"    </a>",
"    ]. Entrapment of the nerve can be caused by intra- or extra-abdominal pressure or localized scarring.",
"   </p>",
"   <p>",
"    A characteristic feature of chronic abdominal wall pain is localization of pain to a highly discrete region of the abdomen (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical manifestations'",
"    </a>",
"    below). This can be explained by the characteristics of the nerves causing the pain. There are two kinds of pain receptors: A-delta and C nociceptors. The A-delta form, comprising up to 25 percent of nociceptors, are found in skin and muscle, and mediate the sharp, sudden pain that is associated with injury such as a cut, trauma, or pain in the abdominal wall. The C type nociceptor (approximately 50 percent of nociceptors) innervates periosteum, parietal peritoneum, and viscera and mediates the dull, difficult to localize pain of intraperitoneal disease. With most causes of intraabdominal pain, localization is difficult and the patient often waves the hand over a relatively wide area of the abdomen (C-type nociceptors). In contrast, when the pain is in the abdominal wall (and, therefore, mediated by A-delta nociceptors) the patient usually points to the location with one finger. There are, however, exceptions to this rule. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=see_link&amp;anchor=H3#H3\">",
"     \"Differential diagnosis of abdominal pain in adults\", section on 'Localization of pain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The processes leading to nerve entrapment are not understood. As mentioned above, cutaneous nerves can become entrapped in areas of postoperative scarring. Other mechanical causes of nerve compression (such as obesity and tight clothing) may also be important in individual cases, but thin patients are also affected. Oral contraceptives and pregnancy have been associated with exacerbation of entrapment syndromes, possibly due to tissue edema from estrogen and progesterone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain associated with nerve entrapment is characteristically maximal in an area less than 2 cm in diameter. In several series, pain was predominantly in the right side of the abdomen, although any location (and more than one location) is possible. The location is often along the lateral aspect of the rectus abdominus muscle sheath.",
"   </p>",
"   <p>",
"    The nature of the pain may be sharp or dull; localization is a much more important diagnostic clue than is the character of the pain. In a few persons, the pain is somewhat more diffuse, with radiation throughout the affected dermatome. Some patients can identify activities that worsen pain, particularly those that cause tensing of abdominal musculature (eg, standing, walking, stretching, laughing, coughing, and sneezing).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis can usually be established by the history and physical examination. A response to treatment with an anesthetic agent (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Treatment'",
"    </a>",
"    below) can provide confirmation.",
"   </p>",
"   <p>",
"    On physical examination, the patient is able to point with one finger to the area of maximal tenderness. One author described a \"hover sign,\" referring to patients who guard the affected area from the examiner's hands [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/2\">",
"     2",
"    </a>",
"    ]. The surrounding skin may have heightened sensitivity to normally non-painful tactile stimulation (allodynia).",
"   </p>",
"   <p>",
"    \"Carnett's\" sign refers to increased local tenderness during muscle tensing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/11\">",
"     11",
"    </a>",
"    ]. While supine, the patient is asked to perform a straight-leg-raising maneuver (raising both legs off the table at the same time) while the examining finger is on the painful site. Raising only the head while in the supine position can serve the same purpose. These maneuvers tighten the rectus abdominis muscles, increasing the pain from the entrapped nerve. If the pain is increased or the same, the source of the patient's symptoms is most likely the abdominal wall, and the Carnett&rsquo;s sign should be considered positive. If the pain is decreased (a negative Carnett's sign), the origin of pain is likely from an intra-abdominal organ, as the tensed abdominal wall muscles protect the viscera.",
"   </p>",
"   <p>",
"    In a study of 130 outpatients with abdominal pain and abdominal tenderness, the positive likelihood ratio of Carnett's sign for abdominal wall pain was 2.62 (95% CI, 2.45-2.81) and the negative likelihood ratio was 0.23 (95% CI, 0.13-0.41) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/12\">",
"     12",
"    </a>",
"    ]. Carnett's sign may not be interpretable in patients who cannot comply adequately with leg or head-raising maneuvers. False positive results may occur from visceral causes of pain that involve the local parietal peritoneum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of abdominal wall pain includes a variety of other causes of localized pain. These include abdominal wall hernias, thoracic nerve radiculopathy, thoracic disk syndrome, and pain generated from the ribcage and chest wall. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=see_link\">",
"     \"Differential diagnosis of abdominal pain in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Abdominal wall hernias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hernias of the abdominal wall (eg, epigastric and Spigelian) may be culprits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/2\">",
"     2",
"    </a>",
"    ]. Epigastric hernias occur in the midline (except at the umbilicus), are often multiple, and are found more often in obese patients. Pain may increase when lying down and a small subcutaneous mass (tag of omentum) may be felt in the linea alba in addition to a defect(s) in the midline. A Spigelian hernia is less common, and difficult to identify. This hernia is a protrusion through the Spigelian fascia (that area of the transversus abdominis aponeurosis lateral to the edge of the rectus sheath but medial to the Spigelian line). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43801?source=see_link\">",
"     \"Overview of abdominal hernias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Surgical scars",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with prior abdominal surgery, a defect can often be felt in the surgical scar, usually at their ends [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/2\">",
"     2",
"    </a>",
"    ]. We have occasionally found defects in trocar insertion sites after laparoscopic surgery. Patients often localize their pain to the above mentioned sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Abdominal wall endometriosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case series described a group of patients with abdominal wall endometriosis, all of whom had undergone a previous Cesarean section [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/13\">",
"     13",
"    </a>",
"    ]. In 11 of 12 patients, endometriosis was detectable with ultrasound with Doppler, and nine had a palpable mass. Of interest is that the symptoms in these patients were often non-cyclic. The authors estimate that 0.8 percent of all women who have had C-sections have abdominal wall endometriosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Thoracic nerve radiculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease in the T7 to T12 nerve roots may cause pain referred to the abdomen. For this reason, careful examination of the spine and back should be performed and imaging studies obtained if appropriate.",
"   </p>",
"   <p>",
"    Diabetic patients may have chronic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    recurring abdominal pain similar to acute painful neuropathy that is often localized to the thighs but may also affect the abdomen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/2,14-16\">",
"     2,14-16",
"    </a>",
"    ]. The pain may last for months but spontaneous recovery is often complete within a year and the condition does not necessarily progress to polyneuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/15\">",
"     15",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"     Amitriptyline",
"    </a>",
"    may help this condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Thoracic disc syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is at least one case report of a spinal cord tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/2\">",
"     2",
"    </a>",
"    ] and one of a thoracic herniated disc [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/18\">",
"     18",
"    </a>",
"    ] that presented as abdominal pain. Pain resolved once the proper diagnosis was made and appropriate therapy administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Pain generated from the ribcage and chest wall",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several observers have identified the chest wall as a cause of upper abdominal pain. Tenderness in the costochondral junctions in the lower chest or xiphoid in the absence of swelling has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/19\">",
"     19",
"    </a>",
"    ]. These symptoms were found more often in women, 90 percent of whom were in the third to sixth decades of life. The xiphoid cartilage syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/20\">",
"     20",
"    </a>",
"    ] or the hypersensitive xiphoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/21\">",
"     21",
"    </a>",
"    ] may cause pain, and sometimes nausea and vomiting, when pressure is applied to the painful spot.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Rectus sheath hematoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A rectus sheath hematoma may be responsible for the acute onset of abdominal wall pain. In a report of 126 cases, about two-thirds of patients were women and about two-thirds were taking anticoagulants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/22\">",
"     22",
"    </a>",
"    ]. The majority presented with abdominal pain, while 60 percent had a palpable mass. Most patients responded to conservative therapy while 8 percent required surgery and 2 percent died as a result of bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Slipping rib syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;First described in 1922, the slipping rib syndrome is rare and is usually associated with unilateral, sharp, stabbing pain localized just beneath the ribs. This may occur at rest and may be increased by movement, especially twisting or turning. The diagnosis is made when the examiner hooks the fingers beneath the lowest rib and the rib is moved anteriorly, reproducing the patient's symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/23\">",
"     23",
"    </a>",
"    ]. Rarely, resection of the rib is required for pain relief.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85708581\">",
"    <span class=\"h2\">",
"     Ribs on pelvis syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ribs on pelvis syndrome typically affects postmenopausal women with loss of vertebral height and kyphosis secondary to osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/24\">",
"     24",
"    </a>",
"    ]. Forward angulation caused by anterior compression fractures pushes the ribs onto the pelvis causing the pain. The pain is usually worse later in the day as physical activity while upright increases the impingement. Treatment consists of physical therapy to improve posture as well as such local measures as heat and analgesics.",
"   </p>",
"   <p>",
"    The costo-iliac impingement syndrome may also cause pain in the back and groin, due to the 12",
"    <sup>",
"     th",
"    </sup>",
"    rib pressing against the pelvic brim [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment depends upon the severity of symptoms. Reassurance and avoidance of precipitating activities may be sufficient in patients with mild symptoms. Localized heat may be soothing during exacerbations. Nonsteroidal antiinflammatory agents and antidepressants can be used but are of limited benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Physical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be advised not to exercise to strengthen abdominal muscles, as vigorous exercise may exacerbate the pain. Patients regularly performing exercises that involve tension of the abdominal muscles (such as abdominal crunches) should be advised to alter their exercise routine. Anecdotal experience suggests that abdominal wall strengthening exercises taught by skilled physical therapists or those familiar with sports injuries relieve symptoms in as many as one-half of patients. The mechanism is unknown, but relief can be complete and permanent. Studies are needed to validate this form of treatment, but it is simple, and can be used by patients long-term if necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Injection therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection of anesthetic agents gives pain relief in 60 to 90 percent of patients, and helps secure the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/1,4,26-30\">",
"     1,4,26-30",
"    </a>",
"    ]. Most reports have been in adults, although successful treatment of children has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A change in diagnosis was uncommon (&lt;10 percent) in most series with long-term follow-up of patients in whom the history and physical examination suggested the diagnosis and who responded to anesthetic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/4,5,7,8,32,33\">",
"     4,5,7,8,32,33",
"    </a>",
"    ]. In one of the largest series, the diagnosis remained unchanged in 97 percent of 137 patients who were followed for an average of almost four years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/7\">",
"     7",
"    </a>",
"    ]. Approximately one-half were pain free at last follow-up.",
"   </p>",
"   <p>",
"    Injections may be quite painful for several seconds, and patients should be so informed. Injection can be done directly into the entrapped nerve, but has also been successful in patients with abdominal pain originating in spinal lesions, using intercostal or epidural nerve blocks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/34\">",
"     34",
"    </a>",
"    ]. In various series, 40 to 80 percent of patients had long-term relief from local injections but others have only short-term benefits. Efficacy may depend upon the breaking of a chronic pain cycle, the mechanical effect of the injected volume in decompressing the entrapped nerve, and a placebo effect.",
"   </p>",
"   <p>",
"    Several variations on the technique and agents used for local injection have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/5,35\">",
"     5,35",
"    </a>",
"    ]. One method involves passing a 1.5 inch 26 gauge needle perpendicularly into a lightly pinched skin and subcutaneous tissue fold at the affected site. Insertion of the needle becomes painful when reaching the tender area. We inject 1 to 3 mL of a 1 percent solution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    into the tender spot and follow it with 1 mL (40) mg of a long-acting steroid (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    ). Pain should resolve within five minutes. It may return in one to two hours once the anesthetic wears off but often does not when the steroid is used.",
"   </p>",
"   <p>",
"    Injection of longer-acting anesthetics with or without corticosteroids has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/5\">",
"     5",
"    </a>",
"    ]. Corticosteroids, with their reported membrane stabilizing effects, may enhance the anesthetic effect. Experimental studies on neuromas suggest that they may also reduce spontaneous, ectopic discharges, possibly also helping to explain their pain-relieving effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/36\">",
"     36",
"    </a>",
"    ]. One group described a 78 percent long-term response (mean 13.8 months) in patients who were treated with an injection of 2 mL of 0.25 percent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    and 20 to 40 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    or a comparable agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/4\">",
"     4",
"    </a>",
"    ]. Pain relief was observed within 72 hours. A repeat injection (days to months later) was necessary in approximately 30 percent of patients. Some patients required the injection of multiple sites in which case the total volume injected was limited to 10 mL to avoid systemic effects.",
"   </p>",
"   <p>",
"    Neurolysis with 5 to 6 percent phenol or absolute alcohol can be considered in responding patients who required more than three reinjections in the same site within a year. Surgical release of entrapped nerves has also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31030/abstract/2,37\">",
"     2,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic pain emanating from the abdominal wall is frequently unrecognized or confused with visceral pain, often leading to extensive diagnostic testing before an accurate diagnosis is achieved. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The exact prevalence of abdominal wall pain is unknown. Five to 10 percent of patients referred to specialist practices in gastroenterology and 20 percent of patients admitted to a surgical department for abdominal pain have abdominal wall pain. Women appear to be four times more likely to have chronic abdominal wall pain than men. The peak incidence is between the ages of 30 to 50 years, although cases have been reported in children and the elderly. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While many conditions can cause chronic pain in the abdomen, the term \"chronic abdominal wall pain\" usually refers to anterior cutaneous nerve entrapment syndrome (ACNES), one of the most common causes of this condition. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain associated with nerve entrapment is characteristically maximal in an area less than 2 cm in diameter and often along the lateral aspect of the rectus abdominus muscle sheath. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis can usually be established by the history and physical examination. Injection of a local anesthetic agent can provide confirmation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Injection of anesthetic agents gives pain relief in 60 to 90 percent of patients with abdominal wall pain while helping secure the diagnosis. Thus, in patients suspected of having abdominal wall pain, we suggest injection of an anesthetic (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See 'Treatment' above.)",
"      <br/>",
"      <br/>",
"      Several variations on the technique and agents used for local injection have been described. One method involves passing a 1.5 inch 26 gauge needle perpendicularly into a lightly pinched skin and subcutaneous tissue fold at the affected site. Insertion of the needle becomes painful when reaching the tender area. We inject 1 to 3 mL of a 1 percent solution of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      into the tender spot and follow it with 1 mL (40) mg of a long-acting steroid (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      ). Pain should resolve within five minutes. It may return in one to two hours once the anesthetic wears off but often does not when the steroid is used. (See 'Injection therapy' above.)",
"     </li>",
"     <li>",
"      Pain relief with local injections has been observed within 72 hours. A repeat injection (days to months later) may be necessary in approximately 30 percent of patients. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Injection therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients requiring three reinjections in the same site within a year, neurolysis with 5 to 6 percent phenol or absolute alcohol can be considered. Surgical release of entrapped nerves has also been described. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Injection therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/1\">",
"      Thompson C, Goodman R, Rowe WA, et al. Abdominal wall syndrome: A costly diagnosis of exclusion (abstract). Gastroenterology 2001; 120:A637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/2\">",
"      Hershfield NB. The abdominal wall. A frequently overlooked source of abdominal pain. J Clin Gastroenterol 1992; 14:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/3\">",
"      Applegate WV. Abdominal cutaneous nerve entrapment syndrome. Surgery 1972; 71:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/4\">",
"      Greenbaum DS, Greenbaum RB, Joseph JG, Natale JE. Chronic abdominal wall pain. Diagnostic validity and costs. Dig Dis Sci 1994; 39:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/5\">",
"      Srinivasan R, Greenbaum DS. Chronic abdominal wall pain: a frequently overlooked problem. Practical approach to diagnosis and management. Am J Gastroenterol 2002; 97:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/6\">",
"      Sharpstone D, Colin-Jones DG. Chronic, non-visceral abdominal pain. Gut 1994; 35:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/7\">",
"      Costanza CD, Longstreth GF, Liu AL. Chronic abdominal wall pain: clinical features, health care costs, and long-term outcome. Clin Gastroenterol Hepatol 2004; 2:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/8\">",
"      Thomson H, Francis DM. Abdominal-wall tenderness: A useful sign in the acute abdomen. Lancet 1977; 2:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/9\">",
"      Peleg R. Abdominal wall pain caused by cutaneous nerve entrapment in an adolescent girl taking oral contraceptive pills. J Adolesc Health 1999; 24:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/10\">",
"      Peleg R, Gohar J, Koretz M, Peleg A. Abdominal wall pain in pregnant women caused by thoracic lateral cutaneous nerve entrapment. Eur J Obstet Gynecol Reprod Biol 1997; 74:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/11\">",
"      Carnett JB. Intercostal neuralgia as a cause of abdominal pain and tenderness. SGO Surg Gynecol Obstet 1926; 42:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/12\">",
"      Takada T, Ikusaka M, Ohira Y, et al. Diagnostic usefulness of Carnett's test in psychogenic abdominal pain. Intern Med 2011; 50:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/13\">",
"      Hensen JH, Van Breda Vriesman AC, Puylaert JB. Abdominal wall endometriosis: clinical presentation and imaging features with emphasis on sonography. AJR Am J Roentgenol 2006; 186:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/14\">",
"      Longstreth GF, Newcomer AD. Abdominal pain caused by diabetic radiculopathy. Ann Intern Med 1977; 86:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/15\">",
"      Longstreth GF. Diabetic thoracic polyradiculopathy: ten patients with abdominal pain. Am J Gastroenterol 1997; 92:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/16\">",
"      Streib EW, Sun SF, Paustian FF, et al. Diabetic thoracic radiculopathy: electrodiagnostic study. Muscle Nerve 1986; 9:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/17\">",
"      Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987; 37:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/18\">",
"      Whitcomb DC, Martin SP, Schoen RE, Jho HD. Chronic abdominal pain caused by thoracic disc herniation. Am J Gastroenterol 1995; 90:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/19\">",
"      Scobie BA. Costochondral pain in gastroenterologic practice. N Engl J Med 1976; 295:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/20\">",
"      Palmer E. Xyphoid cartilage syndrome (quoted in Calabro JJ. Costochondritis. N Engl J Med 1977; 296:946).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/21\">",
"      The hypersensitive xiphoid. Lancet 1955; 2:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/22\">",
"      Cherry WB, Mueller PS. Rectus sheath hematoma: review of 126 cases at a single institution. Medicine (Baltimore) 2006; 85:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/23\">",
"      Heinz GJ, Zavala DC. Slipping rib syndrome. JAMA 1977; 237:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/24\">",
"      Simpson C, Greenough WB 3rd. Abdominal pain in an elderly osteoporotic patient: ribs on pelvis syndrome. J Am Geriatr Soc 2004; 52:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/25\">",
"      Wynne AT, Nelson MA, Nordin BE. Costo-iliac impingement syndrome. J Bone Joint Surg Br 1985; 67:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/26\">",
"      McGrady EM, Marks RL. Treatment of abdominal nerve entrapment syndrome using a nerve stimulator. Ann R Coll Surg Engl 1988; 70:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/27\">",
"      Gallegos NC, Hobsley M. Recognition and treatment of abdominal wall pain. J R Soc Med 1989; 82:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/28\">",
"      Tung AS, Tenicela R, Giovanitti J. Rectus abdominis nerve entrapment syndrome. JAMA 1978; 240:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/29\">",
"      Nazareno J, Ponich T, Gregor J. Long-term follow-up of trigger point injections for abdominal wall pain. Can J Gastroenterol 2005; 19:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/30\">",
"      Boelens OB, Scheltinga MR, Houterman S, Roumen RM. Randomized clinical trial of trigger point infiltration with lidocaine to diagnose anterior cutaneous nerve entrapment syndrome. Br J Surg 2013; 100:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/31\">",
"      Skinner AV, Lauder GR. Rectus sheath block: successful use in the chronic pain management of pediatric abdominal wall pain. Paediatr Anaesth 2007; 17:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/32\">",
"      Thomson WH, Dawes RF, Carter SS. Abdominal wall tenderness: a useful sign in chronic abdominal pain. Br J Surg 1991; 78:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/33\">",
"      Gray DW, Dixon JM, Seabrook G, Collin J. Is abdominal wall tenderness a useful sign in the diagnosis of non-specific abdominal pain? Ann R Coll Surg Engl 1988; 70:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/34\">",
"      Ashby EC. Abdominal pain of spinal origin. Value of intercostal block. Ann R Coll Surg Engl 1977; 59:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/35\">",
"      Bourne IH. Treatment of painful conditions of the abdominal wall with local injections. Practitioner 1980; 224:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/36\">",
"      Devor M, Govrin-Lippmann R, Raber P. Corticosteroids suppress ectopic neural discharge originating in experimental neuromas. Pain 1985; 22:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31030/abstract/37\">",
"      Hahn L. Clinical findings and results of operative treatment in ilioinguinal nerve entrapment syndrome. Br J Obstet Gynaecol 1989; 96:1080.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2586 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-F3B3B15694-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_19_31030=[""].join("\n");
var outline_f30_19_31030=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Abdominal wall hernias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Surgical scars",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Abdominal wall endometriosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Thoracic nerve radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Thoracic disc syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Pain generated from the ribcage and chest wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Rectus sheath hematoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Slipping rib syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85708581\">",
"      Ribs on pelvis syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Physical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Injection therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/30/16874?source=related_link\">",
"      Differential diagnosis of abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/49/43801?source=related_link\">",
"      Overview of abdominal hernias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_19_31031="Pathogenesis of fibromyalgia";
var content_f30_19_31031=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of fibromyalgia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/19/31031/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/19/31031/contributors\">",
"     Don L Goldenberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/19/31031/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/19/31031/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/19/31031/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/19/31031/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/19/31031/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibromyalgia is a chronic pain disorder with unknown etiology and unclear pathophysiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence that a single event &ldquo;causes&rdquo; fibromyalgia. Rather, many physical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    emotional stressors may trigger or aggravate symptoms. These have included certain infections, such as a viral illness or Lyme disease, as well as emotional or physical trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A detailed description of the clinical manifestations of fibromyalgia and an approach to the diagnosis of fibromyalgia in adults and children are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8056?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7896?source=see_link\">",
"     \"Clinical manifestations and diagnosis of fibromyalgia in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fibromyalgia is only one of many causes of widespread pain. A discussion of the differential diagnosis of fibromyalgia and the broad differential diagnosis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35608?source=see_link\">",
"     \"Differential diagnosis of fibromyalgia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibromyalgia is considered to be a disorder of pain regulation, classified often under the term central sensitization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/1,2,4\">",
"     1,2,4",
"    </a>",
"    ]. Fibromyalgia shares several features with other common pain disorders that are considered to be more central rather than peripheral pain conditions, such as migraine, tension headaches, temporomandibular joint disorder, and irritable bowel syndrome; these features include common genetic and central nervous system pain processing characteristics.",
"   </p>",
"   <p>",
"    During much of the 20th century, fibromyalgia was thought to be a muscle disease. However, controlled trials found no evidence for significant pathologic or biochemical muscle abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/1-3,5,6\">",
"     1-3,5,6",
"    </a>",
"    ]. As an example, measures of muscle function, including force generation and lactate production during exercise, and muscle pain following exertion are remarkably similar in women with fibromyalgia (FM) and sedentary female controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Most investigators now believe that any muscle pathology is secondary to pain and inactivity rather than primary in nature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/1,6-8\">",
"     1,6-8",
"    </a>",
"    ]; however, some reports suggest that oxidative stress and mitochondrial dysfunction may play a role in the disease process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Genetic predisposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of observational and biologic studies suggest that chronic widespread pain and fibromyalgia have, in part, a genetic basis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/10\">",
"     10",
"    </a>",
"    ]. First degree relatives of patients with FM are 8.5 times more likely to have FM than relatives of patients with rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/11\">",
"     11",
"    </a>",
"    ]. Familial aggregation of lowered thresholds for pressure-induced pain has been documented in first degree relatives of patients. Such reports suggest a shared hereditary factor that may account for the overlap of chronic pain and mood disorders in families. However, no association between chronic widespread pain and any candidate gene has yet been conclusively documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Candidate genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability of some antidepressant drugs to improve symptoms suggested that genes involved in serotonin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    catecholamine metabolic or signaling pathways might be candidates for conferring susceptibility. Initial studies failed to identify significant associations between FM and three genetic markers with hypothesis-driven clinical relevance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/13\">",
"     13",
"    </a>",
"    ]. Examples of studies of genes involving these pathways include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human serotonin transporter gene &mdash; An increased propensity to have inherited deletions in the gene for the human serotonin transporter suggests an underlying genetic component for the heightened pain sensation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. However, this putative association may be limited to patients with concomitant affective disorders, as it was not confirmed in patients with FM without depression or anxiety [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/16\">",
"       16",
"      </a>",
"      ]. For example, there was no evidence for abnormal polymorphism of the serotonin transporter gene in one report in FM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Catecholamine methyltransferase genes &mdash; Catecholamine methyltransferase (COMT) genes that have been incriminated in predisposition to both pain and depression have also been implicated in FM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/18\">",
"       18",
"      </a>",
"      ]. There was an association between FM and the COMT val (158) met polymorphism, and the effect of the COMT genotype correlated with the number of pressure points reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/19\">",
"       19",
"      </a>",
"      ]. Also, unaffected relatives of the FM patients had a reduced percentage of the COMT met allele.",
"      <br/>",
"      <br/>",
"      Another report suggested an interaction in fibromyalgia for COMT and correlated the genetic influence with pain levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/20\">",
"       20",
"      </a>",
"      ]. Fibromyalgia patients with",
"      <span class=\"nowrap\">",
"       met/met",
"      </span>",
"      COMT genotype experienced a greater decline in positive effect on days when pain was elevated than did either",
"      <span class=\"nowrap\">",
"       val/met",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       val/val",
"      </span>",
"      individuals.",
"      <br/>",
"      <br/>",
"      DRD3 Ser9Gly polymorphism was found to influence DNIC efficacy and pain tolerance in FM patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Polymorphism of adrenergic receptors &mdash; There has been evidence for the association of FM and symptom severity with various adrenergic receptor gene polymorphisms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional studies have identified selected genes of interest. A much larger candidate gene study than that described above evaluated 496 fibromyalgia patients and 348 chronic pain-free controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/23\">",
"     23",
"    </a>",
"    ]. Significant differences in allele frequencies between fibromyalgia cases and controls were observed for three genes: GABRB3 (rs4906902, p = 3.65x10",
"    <sup>",
"     -6",
"    </sup>",
"    ), TAAR1 (rs8192619, p = 1.11x10",
"    <sup>",
"     -5",
"    </sup>",
"    ), and GBP1 (rs7911, p = 1.06x10",
"    <sup>",
"     -4",
"    </sup>",
"    ). These three genes and seven other genes with suggestive evidence for association were examined in a second, independent cohort of FM patients and controls genotyped using the Perlegen 600K platform. Evidence of association in the replication cohort was observed for TAAR1, RGS4, CNR1, and GRIA4 genes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Altered pain processing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alterations in pain and sensory processing in the central nervous system are present in FM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients perceive noxious stimuli, such as heat, electrical current, or pressure, as being painful at lower levels of physical stimulation than do healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/1,2,5,25\">",
"     1,2,5,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence of altered pain processing includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temporal and spatial summation of pain &mdash; FM patients experience greater than normal increases in the perceived intensity of pain when rapidly repetitive short noxious stimuli are administered, which is termed temporal summation of pain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/26\">",
"       26",
"      </a>",
"      ]. Spatial summation of pain, in which increasing the area of noxious stimulation results in a decreased pain threshold or an increase in perceived pain intensity, may also play a role in FM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/26,27\">",
"       26,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Decreased endogenous pain inhibition &mdash; Endogenous analgesic systems appear to be deficient in FM [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/24,28\">",
"       24,28",
"      </a>",
"      ]. There are both a reduction in diffuse noxious inhibitory control (in which decreased pain occurs upon stimulation with a second acutely painful stimulus) and an inability to inhibit irrelevant sensory stimuli following repetitive nonpainful stimulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/27,29\">",
"       27,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pain receptors and pain-related neuropeptides &mdash; Changes are seen in opioid receptors, including upregulation in the periphery and a reduction in the brain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]. Substance P, a neuropeptide associated with chronic pain states, is increased in the cerebrospinal fluid compared with controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/32\">",
"       32",
"      </a>",
"      ]. Increased brain and plasma brain-derived neurotrophic factor have been found in fibromyalgia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Functional neuroimaging &mdash; Differences in activation of pain-sensitive areas of the brain have been demonstrated by functional neuroimaging techniques, such as functional magnetic resonance imaging [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/34-37\">",
"       34-37",
"      </a>",
"      ]. Areas of the brain that consistently exhibit greater activation after the same stimulus in FM patients than controls include the secondary somatosensory cortex, insula, and anterior cingulate cortex [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/24\">",
"       24",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      More limited data, using positron emission tomography, have shown reduced dopaminergic activity in the response to pain in patients with FM compared with controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/38,39\">",
"       38,39",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Functional MRI was used to compare brain activity during the anticipation of pain with the amount of the impending pain in FM, RA, and control patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/40\">",
"       40",
"      </a>",
"      ]. A unique temporal brain activation of the frontal cortex was noted in patients with FM, and areas of the motor cortex and the cingulate cortex presented a FM-specific relation between brain activity during pain anticipation and the magnitude of the subsequent pain experience.",
"     </li>",
"     <li>",
"      Affective and cognitive factors &mdash; Both affective and cognitive factors influence pain processing in the central nervous system [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/1,2,35\">",
"       1,2,35",
"      </a>",
"      ]. Patients with FM and comorbid depression demonstrate increased cerebral blood flow in the amygdala and anterior insula, areas important in the affective pain response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/35\">",
"       35",
"      </a>",
"      ]. However, unlike FM, depression does not seem to affect the level of neuronal activation in sensory pain regions such as the secondary somatosensory cortex [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Morphometric analysis &mdash; Morphometric analysis by magnetic resonance imaging in patients with FM shows, compared with healthy controls, a significant reduction in total gray matter volume and a threefold increase in age-associated loss of gray matter, suggesting premature aging of the brain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/41\">",
"       41",
"      </a>",
"      ]. The degree of loss was greater in patients with a longer duration of disease. Such gray matter loss, which is also reported in other chronic pain and stress-related disorders, was most prominent in regions related to stress and pain processing but was also seen in areas related to cognitive function. Another study revealed similar findings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/42\">",
"       42",
"      </a>",
"      ]. However, another group found no significant difference in gray matter between FM patients and controls when controlling for depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Using proton magnetic resonance spectroscopy, FM patients had significantly higher levels of glutamine within the right posterior insula compared with controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/44\">",
"       44",
"      </a>",
"      ]. Elevated insular glutamate in fibromyalgia is associated with experimental pain. Within the right posterior insula, higher levels of glutamate were associated with lower pressure pain thresholds.",
"     </li>",
"     <li>",
"      Patients with fibromyalgia were evaluated for cortical excitability and intracortical modulation using transcranial magnetic stimulation of the motor cortex [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/45\">",
"       45",
"      </a>",
"      ]. The fibromyalgia patients compared with controls had deficits in intracortical modulation of GABAergic and glutamatergic mechanisms.",
"     </li>",
"     <li>",
"      Using MR spectroscopy, FM patients showed higher levels of glutamate and a higher",
"      <span class=\"nowrap\">",
"       glutamine-glutamate/creatine",
"      </span>",
"      ratio in the right amygdala compared with controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/46\">",
"       46",
"      </a>",
"      ]. In the FM patients with more pain, fatigue and depressive symptoms inositol (Ins) levels were found to be significantly higher in the right amygdala and right thalamus.",
"     </li>",
"     <li>",
"      Using proton MR spectroscopy, GABA levels in the right anterior insula were significantly lower in FM patients compared with healthy controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/47\">",
"       47",
"      </a>",
"      ]. No significant differences between groups were detected in the posterior insula or occipital cortex. Within the right posterior insula, higher levels of GABA were positively correlated with pressure-pain thresholds in the FM patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Sleep abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Underlying central nervous system dysfunction is suggested by the sleep and mood disturbances noted in the majority of FM patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/1,2,48\">",
"     1,2,48",
"    </a>",
"    ]. Phasic alpha sleep activity is most characteristic of FM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/49\">",
"     49",
"    </a>",
"    ]. An increase in cyclic alternating patterns of sleep has been noted in FM and has been correlated with the severity of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/50\">",
"     50",
"    </a>",
"    ]. Some data suggest that disordered sleep patterns precede the development of pain and that abnormal sleep and pain predict depressive symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A longitudinal study of 12,350 women in Norway who did not have musculoskeletal pain or physical impairments at baseline found incident fibromyalgia in 327 women at follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/51\">",
"     51",
"    </a>",
"    ]. There was a dose-dependent association between sleep problems and risk of fibromyalgia, with an adjusted relative risk (RR) of FM of 3.43 (95% CI 2.26-5.19) among women who reported having sleep problems often or always, compared with women who never experienced sleep problems. Age-stratified analysis showed that women age&ge;45 years who reported having sleep problems often or always had an adjusted RR of FM of 5.41 (95% CI 2.65-11.05), while the corresponding RR for women ages 20 to 44 years who reported having sleep problems often or always was 2.98 (95% CI 1.76-5.05).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neurohormonal perturbations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperactivity of the stress response, demonstrated by abnormalities of the hypothalamic-pituitary-adrenal (HPA) axis, has been found using different baseline and provocative testing, although the precise nature of these changes has not been elucidated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/52-57\">",
"     52-57",
"    </a>",
"    ]. Some neurohormonal abnormalities have included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A correlation between cerebrospinal levels of corticotropin-releasing factor, sensory pain, and variation in autonomic function in fibromyalgia that was not associated with chronic fatigue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/54\">",
"       54",
"      </a>",
"      ]. Altered HPA axis activity may be linked to childhood trauma, especially physical abuse [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A strong correlation between cortisol levels and pain upon awakening and one hour after waking in patients with FM compared with controls [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/56\">",
"       56",
"      </a>",
"      ]. Correlations were made between HPA axis function and lymphocyte glucocorticoid reaction in FM patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Abnormal levels of growth hormone in some but not all reports [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/59\">",
"       59",
"      </a>",
"      ]. There is no good evidence to suggest that there are alterations of sex hormones in fibromyalgia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Autonomic nervous system dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal function of the autonomic nervous system in those with fibromyalgia (FM) is suggested by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with FM have been found to have orthostatic hypotension, and increased pain was noted in response to tilt table testing. Fibromyalgia patients also had significantly abnormal values in a number of autonomic tests as determined by the Composite Autonomic Symptom Scale (COMPASS). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/45/3799?source=see_link\">",
"       \"Evaluation of parasympathetic nervous system function\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Decreased responsiveness to beta-adrenergic stimulation in those with FM was demonstrated by in-vitro testing of beta adrenergic receptor mediated cyclic AMP generation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/61\">",
"       61",
"      </a>",
"      ]. The alterations of cardiovascular regulation that had been postulated to be pathologically important in fibromyalgia are significantly affected by deconditioning [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a study involving 58 women, including FM patients and healthy age-matched controls, urinary catecholamines and heart rate were assessed for a 24-hour period in a controlled hospital setting (including relaxation, a test with prolonged mental stress, and sleep) and during daily activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/63\">",
"       63",
"      </a>",
"      ].The catecholamine levels were lower in FM patients than in controls. Patients with FM had significantly lower adrenaline levels during the night and the second day and had significantly lower dopamine levels during the first day, the night, and the second day. Overall, heart rate was significantly higher in patients than in controls.",
"     </li>",
"     <li>",
"      In another approach, plasma catecholamines, ACTH, and cortisol were reduced in 16 fibromyalgia patients compared with 16 healthy controls as they performed static knee extension until exhaustion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nocturnal heart rate variability indices were significantly different in FM women compared with healthy individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/65\">",
"       65",
"      </a>",
"      ]. In FM patients, these HRV parameters correlated with several symptoms including pain severity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Immune system changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is little evidence to support the concept that FM is an immune mediated disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Autoantibodies with affinity for a",
"    <span class=\"nowrap\">",
"     68/48",
"    </span>",
"    kD protein have been found in a subset of patients with FM but not in healthy controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/66\">",
"     66",
"    </a>",
"    ]. Other cytokine changes have been reported, but no studies have been consistent or controlled well for mood disturbances and activity levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis concluded that the role of cytokines in FM is unclear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/68\">",
"     68",
"    </a>",
"    ]. In general, FM patients had higher serum levels of interleukin (IL)-1 receptor antagonist, IL-6, and IL-8 and had higher plasma levels of IL-8. Meta-analysis of eligible studies showed that FM patients had higher plasma IL-6 levels compared with controls (standardized mean difference = -0.34 [95% CI -0.64 to -0.03]). The majority of investigated cytokines did not differ between patients and controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12284305\">",
"    <span class=\"h2\">",
"     Peripheral pain mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibromyalgia patients often have focal tissue abnormalities including myofascial trigger points, ligamentous trigger points, or osteoarthritis of the joints and spine. These are important peripheral pain generators that may initiate or perpetuate chronic pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sustained isometric muscle contraction recruits segmental",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extrasegmental descending inhibition in healthy subjects but not in fibromyalgia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31031/abstract/70\">",
"     70",
"    </a>",
"    ]. Descending pain modulation shifts from descending inhibition toward descending facilitation following muscle nociception in FM. Peripheral mechanical hyperalgesia and descending facilitation counterbalance the effect of descending inhibition in FM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is conclusive evidence that alterations in central nervous system pain processing are responsible for many of the features of fibromyalgia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Altered pain processing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Genetic and environmental factors likely interact to promote a state of chronic central and peripheral nervous system hyperirritability. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Genetic predisposition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Candidate genes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/1\">",
"      Sarzi-Puttini P, Atzeni F, Mease PJ. Chronic widespread pain: from peripheral to central evolution. Best Pract Res Clin Rheumatol 2011; 25:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/2\">",
"      Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology to therapy. Nat Rev Rheumatol 2011; 7:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/3\">",
"      Goldenberg DL. Do infections trigger fibromyalgia? Arthritis Rheum 1993; 36:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/4\">",
"      Staud R. Abnormal pain modulation in patients with spatially distributed chronic pain: fibromyalgia. Rheum Dis Clin North Am 2009; 35:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/5\">",
"      Meeus M, Nijs J. Central sensitization: a biopsychosocial explanation for chronic widespread pain in patients with fibromyalgia and chronic fatigue syndrome. Clin Rheumatol 2007; 26:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/6\">",
"      Simms RW, Roy SH, Hrovat M, et al. Lack of association between fibromyalgia syndrome and abnormalities in muscle energy metabolism. Arthritis Rheum 1994; 37:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/7\">",
"      H&auml;kkinen A, H&auml;kkinen K, Hannonen P, Alen M. Force production capacity and acute neuromuscular responses to fatiguing loading in women with fibromyalgia are not different from those of healthy women. J Rheumatol 2000; 27:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/8\">",
"      Lund E, Kendall SA, Janerot-Sj&oslash;berg B, Bengtsson A. Muscle metabolism in fibromyalgia studied by P-31 magnetic resonance spectroscopy during aerobic and anaerobic exercise. Scand J Rheumatol 2003; 32:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/9\">",
"      Cordero MD, de Miguel M, Carmona-L&oacute;pez I, et al. Oxidative stress and mitochondrial dysfunction in fibromyalgia. Neuro Endocrinol Lett 2010; 31:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/10\">",
"      Buskila D, Sarzi-Puttini P. Biology and therapy of fibromyalgia. Genetic aspects of fibromyalgia syndrome. Arthritis Res Ther 2006; 8:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/11\">",
"      Arnold LM, Hudson JI, Hess EV, et al. Family study of fibromyalgia. Arthritis Rheum 2004; 50:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/12\">",
"      Limer KL, Nicholl BI, Thomson W, McBeth J. Exploring the genetic susceptibility of chronic widespread pain: the tender points in genetic association studies. Rheumatology (Oxford) 2008; 47:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/13\">",
"      Ablin JN, Bar-Shira A, Yaron M, Orr-Urtreger A. Candidate-gene approach in fibromyalgia syndrome: association analysis of the genes encoding substance P receptor, dopamine transporter and alpha1-antitrypsin. Clin Exp Rheumatol 2009; 27:S33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/14\">",
"      Offenbaecher M, Bondy B, de Jonge S, et al. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 1999; 42:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/15\">",
"      Cohen H, Buskila D, Neumann L, Ebstein RP. Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5- HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis Rheum 2002; 46:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/16\">",
"      Gursoy S. Absence of association of the serotonin transporter gene polymorphism with the mentally healthy subset of fibromyalgia patients. Clin Rheumatol 2002; 21:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/17\">",
"      Potvin S, Larouche A, Normand E, et al. No relationship between the ins del polymorphism of the serotonin transporter promoter and pain perception in fibromyalgia patients and healthy controls. Eur J Pain 2010; 14:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/18\">",
"      G&uuml;rsoy S, Erdal E, Herken H, et al. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int 2003; 23:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/19\">",
"      Cohen H, Neumann L, Glazer Y, et al. The relationship between a common catechol-O-methyltransferase (COMT) polymorphism val(158) met and fibromyalgia. Clin Exp Rheumatol 2009; 27:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/20\">",
"      Finan PH, Zautra AJ, Davis MC, et al. Genetic influences on the dynamics of pain and affect in fibromyalgia. Health Psychol 2010; 29:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/21\">",
"      Potvin S, Larouche A, Normand E, et al. DRD3 Ser9Gly polymorphism is related to thermal pain perception and modulation in chronic widespread pain patients and healthy controls. J Pain 2009; 10:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/22\">",
"      Vargas-Alarc&oacute;n G, Fragoso JM, Cruz-Robles D, et al. Association of adrenergic receptor gene polymorphisms with different fibromyalgia syndrome domains. Arthritis Rheum 2009; 60:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/23\">",
"      Smith SB, Maixner DW, Fillingim RB, et al. Large candidate gene association study reveals genetic risk factors and therapeutic targets for fibromyalgia. Arthritis Rheum 2012; 64:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/24\">",
"      Dadabhoy D, Crofford LJ, Spaeth M, et al. Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome. Arthritis Res Ther 2008; 10:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/25\">",
"      Desmeules JA, Cedraschi C, Rapiti E, et al. Neurophysiologic evidence for a central sensitization in patients with fibromyalgia. Arthritis Rheum 2003; 48:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/26\">",
"      Staud R, Koo E, Robinson ME, Price DD. Spatial summation of mechanically evoked muscle pain and painful aftersensations in normal subjects and fibromyalgia patients. Pain 2007; 130:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/27\">",
"      Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain 2005; 114:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/28\">",
"      Jensen KB, Kosek E, Petzke F, et al. Evidence of dysfunctional pain inhibition in Fibromyalgia reflected in rACC during provoked pain. Pain 2009; 144:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/29\">",
"      Montoya P, Sitges C, Garc&iacute;a-Herrera M, et al. Reduced brain habituation to somatosensory stimulation in patients with fibromyalgia. Arthritis Rheum 2006; 54:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/30\">",
"      Salemi S, Aeschlimann A, Wollina U, et al. Up-regulation of delta-opioid receptors and kappa-opioid receptors in the skin of fibromyalgia patients. Arthritis Rheum 2007; 56:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/31\">",
"      Harris RE, Clauw DJ, Scott DJ, et al. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci 2007; 27:10000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/32\">",
"      Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994; 37:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/33\">",
"      Haas L, Portela LV, B&ouml;hmer AE, et al. Increased plasma levels of brain derived neurotrophic factor (BDNF) in patients with fibromyalgia. Neurochem Res 2010; 35:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/34\">",
"      Kwiatek R, Barnden L, Tedman R, et al. Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum 2000; 43:2823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/35\">",
"      Giesecke T, Gracely RH, Williams DA, et al. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum 2005; 52:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/36\">",
"      Emad Y, Ragab Y, Zeinhom F, et al. Hippocampus dysfunction may explain symptoms of fibromyalgia syndrome. A study with single-voxel magnetic resonance spectroscopy. J Rheumatol 2008; 35:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/37\">",
"      Lutz J, J&auml;ger L, de Quervain D, et al. White and gray matter abnormalities in the brain of patients with fibromyalgia: a diffusion-tensor and volumetric imaging study. Arthritis Rheum 2008; 58:3960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/38\">",
"      Wood PB, Patterson JC 2nd, Sunderland JJ, et al. Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study. J Pain 2007; 8:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/39\">",
"      Wood PB, Schweinhardt P, Jaeger E, et al. Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci 2007; 25:3576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/40\">",
"      Burgmer M, Pogatzki-Zahn E, Gaubitz M, et al. Fibromyalgia unique temporal brain activation during experimental pain: a controlled fMRI Study. J Neural Transm 2010; 117:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/41\">",
"      Kuchinad A, Schweinhardt P, Seminowicz DA, et al. Accelerated brain gray matter loss in fibromyalgia patients: premature aging of the brain? J Neurosci 2007; 27:4004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/42\">",
"      Burgmer M, Gaubitz M, Konrad C, et al. Decreased gray matter volumes in the cingulo-frontal cortex and the amygdala in patients with fibromyalgia. Psychosom Med 2009; 71:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/43\">",
"      Hsu MC, Harris RE, Sundgren PC, et al. No consistent difference in gray matter volume between individuals with fibromyalgia and age-matched healthy subjects when controlling for affective disorder. Pain 2009; 143:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/44\">",
"      Harris RE, Sundgren PC, Craig AD, et al. Elevated insular glutamate in fibromyalgia is associated with experimental pain. Arthritis Rheum 2009; 60:3146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/45\">",
"      Mhalla A, de Andrade DC, Baudic S, et al. Alteration of cortical excitability in patients with fibromyalgia. Pain 2010; 149:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/46\">",
"      Vald&eacute;s M, Collado A, Bargall&oacute; N, et al. Increased glutamate/glutamine compounds in the brains of patients with fibromyalgia: a magnetic resonance spectroscopy study. Arthritis Rheum 2010; 62:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/47\">",
"      Foerster BR, Petrou M, Edden RA, et al. Reduced insular &gamma;-aminobutyric acid in fibromyalgia. Arthritis Rheum 2012; 64:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/48\">",
"      Moldofsky H. The significance of dysfunctions of the sleeping/waking brain to the pathogenesis and treatment of fibromyalgia syndrome. Rheum Dis Clin North Am 2009; 35:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/49\">",
"      Roizenblatt S, Neto NS, Tufik S. Sleep disorders and fibromyalgia. Curr Pain Headache Rep 2011; 15:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/50\">",
"      Rizzi M, Sarzi-Puttini P, Atzeni F, et al. Cyclic alternating pattern: a new marker of sleep alteration in patients with fibromyalgia? J Rheumatol 2004; 31:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/51\">",
"      Mork PJ, Nilsen TI. Sleep problems and risk of fibromyalgia: longitudinal data on an adult female population in Norway. Arthritis Rheum 2012; 64:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/52\">",
"      Adler GK, Kinsley BT, Hurwitz S, et al. Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. Am J Med 1999; 106:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/53\">",
"      Torpy DJ, Papanicolaou DA, Lotsikas AJ, et al. Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: a pilot study in fibromyalgia. Arthritis Rheum 2000; 43:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/54\">",
"      McLean SA, Williams DA, Stein PK, et al. Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. Neuropsychopharmacology 2006; 31:2776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/55\">",
"      Weissbecker I, Floyd A, Dedert E, et al. Childhood trauma and diurnal cortisol disruption in fibromyalgia syndrome. Psychoneuroendocrinology 2006; 31:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/56\">",
"      McLean SA, Williams DA, Harris RE, et al. Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgia. Arthritis Rheum 2005; 52:3660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/57\">",
"      Geenen R, Bijlsma JW. Deviations in the endocrine system and brain of patients with fibromyalgia: cause or consequence of pain and associated features? Ann N Y Acad Sci 2010; 1193:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/58\">",
"      Wingenfeld K, Heim C, Schmidt I, et al. HPA axis reactivity and lymphocyte glucocorticoid sensitivity in fibromyalgia syndrome and chronic pelvic pain. Psychosom Med 2008; 70:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/59\">",
"      Jones KD, Deodhar P, Lorentzen A, et al. Growth hormone perturbations in fibromyalgia: a review. Semin Arthritis Rheum 2007; 36:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/60\">",
"      El Maghraoui A, Tellal S, Achemlal L, et al. Bone turnover and hormonal perturbations in patients with fibromyalgia. Clin Exp Rheumatol 2006; 24:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/61\">",
"      Maekawa K, Twe C, Lotaif A, et al. Function of beta-adrenergic receptors on mononuclear cells in female patients with fibromyalgia. J Rheumatol 2003; 30:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/62\">",
"      Kadetoff D, Kosek E. The effects of static muscular contraction on blood pressure, heart rate, pain ratings and pressure pain thresholds in healthy individuals and patients with fibromyalgia. Eur J Pain 2007; 11:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/63\">",
"      Riva R, Mork PJ, Westgaard RH, et al. Catecholamines and heart rate in female fibromyalgia patients. J Psychosom Res 2012; 72:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/64\">",
"      Kadetoff D, Kosek E. Evidence of reduced sympatho-adrenal and hypothalamic-pituitary activity during static muscular work in patients with fibromyalgia. J Rehabil Med 2010; 42:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/65\">",
"      Lerma C, Martinez A, Ruiz N, et al. Nocturnal heart rate variability parameters as potential fibromyalgia biomarker: correlation with symptoms severity. Arthritis Res Ther 2011; 13:R185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/66\">",
"      Nishikai M, Tomomatsu S, Hankins RW, et al. Autoantibodies to a 68/48 kDa protein in chronic fatigue syndrome and primary fibromyalgia: a possible marker for hypersomnia and cognitive disorders. Rheumatology (Oxford) 2001; 40:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/67\">",
"      Bazzichi L, Rossi A, Massimetti G, et al. Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin Exp Rheumatol 2007; 25:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/68\">",
"      U&ccedil;eyler N, H&auml;user W, Sommer C. Systematic review with meta-analysis: cytokines in fibromyalgia syndrome. BMC Musculoskelet Disord 2011; 12:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/69\">",
"      Staud R. Peripheral pain mechanisms in chronic widespread pain. Best Pract Res Clin Rheumatol 2011; 25:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31031/abstract/70\">",
"      Ge HY, Nie H, Graven-Nielsen T, et al. Descending pain modulation and its interaction with peripheral sensitization following sustained isometric muscle contraction in fibromyalgia. Eur J Pain 2012; 16:196.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5626 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-0D0D3C1A28-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_19_31031=[""].join("\n");
var outline_f30_19_31031=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Genetic predisposition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Candidate genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Altered pain processing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Sleep abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neurohormonal perturbations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Autonomic nervous system dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Immune system changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12284305\">",
"      Peripheral pain mechanisms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8056?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7896?source=related_link\">",
"      Clinical manifestations and diagnosis of fibromyalgia in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35608?source=related_link\">",
"      Differential diagnosis of fibromyalgia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/45/3799?source=related_link\">",
"      Evaluation of parasympathetic nervous system function",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_19_31032="Pityriasis rubra pilaris follicular papules in dark skin";
var content_f30_19_31032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Pityriasis rubra pilaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 406px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperkeratotic follicular papules in pityriasis rubra pilaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_19_31032=[""].join("\n");
var outline_f30_19_31032=null;
var title_f30_19_31033="Evaluation of carotid artery stenosis";
var content_f30_19_31033=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of carotid artery stenosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/19/31033/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/19/31033/contributors\">",
"     Karen L Furie, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/19/31033/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/19/31033/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/19/31033/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/19/31033/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/19/31033/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/19/31033/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/19/31033/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomographic (CT) scanning and magnetic resonance imaging (MRI) are useful for evaluating the question of cerebral infarction which may result from carotid artery stenosis. Infarctions related to internal carotid artery stenosis may be deep, subcortical, or cortical. However, carotid stenosis may exist in the absence of infarction on MRI and CT.",
"   </p>",
"   <p>",
"    The definition of asymptomatic or symptomatic carotid artery stenosis is based upon the history and physical examination, depending upon whether or not there are symptoms or signs of carotid territory ischemia. In the large clinical trials addressing the management of carotid artery stenosis, the detection of \"silent\" infarcts on CT or MRI did not qualify the stenosis as symptomatic. In clinical practice, however, radiographic evidence of ischemia in the territory of a stenotic internal carotid artery may affect management.",
"   </p>",
"   <p>",
"    Four diagnostic modalities are used to directly image the internal carotid artery:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cerebral angiography",
"     </li>",
"     <li>",
"      Carotid duplex ultrasound",
"     </li>",
"     <li>",
"      Magnetic resonance angiography",
"     </li>",
"     <li>",
"      Computed tomographic angiography",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review the clinical use of these different techniques and their unique advantages and disadvantages. In addition, we will review the different methods of measuring the degree of carotid stenosis used with angiography. Other aspects of carotid disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/24/9608?source=see_link\">",
"     \"Pathophysiology of symptoms from carotid atherosclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21530?source=see_link\">",
"     \"Management of symptomatic carotid atherosclerotic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/33/16922?source=see_link\">",
"     \"Management of asymptomatic carotid atherosclerotic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STENOSIS MEASUREMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The methods of evaluating the degree of angiographic stenosis vary in technique and accuracy. If the results of clinical trials are to be generalized, there is a need for uniformity in measurement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two major randomized clinical trials evaluating the utility of endarterectomy in symptomatic patients used different methods to measure carotid stenosis (",
"    <a class=\"graphic graphic_figure graphicRef58353 \" href=\"mobipreview.htm?11/36/11842\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21530?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of symptomatic carotid atherosclerotic disease\", section on 'Carotid endarterectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Currently, three methods (NASCET, ECST, and CC) predominate worldwide. Although all three were originally devised for use with conventional contrast angiography, these methods can also be used with magnetic resonance and computed tomography angiography.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The North American Symptomatic Carotid Endarterectomy Trial (NASCET) method measures the residual lumen diameter at the most stenotic portion of the vessel and compares this to the lumen diameter in the normal internal carotid artery distal to the stenosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The European Carotid Surgery Trial (ECST) method measures the lumen diameter at the most stenotic portion of the vessel and compares this to the estimated probable original diameter at the site of maximum stenosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The common carotid (CC) method measures the residual lumen diameter at the most stenotic portion of the vessel and compares this to the lumen diameter in the proximal common carotid artery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/2,5\">",
"       2,5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The maximum stenosis is generally in the carotid bulb, a wider portion of the artery than the distal segment. As a result, the same degree of stenosis is quantified as a higher percentage stenosis when measured by the ECST or CC methods than when measured by the NASCET method. The ECST methodology also requires an assumption of the true lumen, which increases the risk of interobserver variability. (",
"    <a class=\"graphic graphic_figure graphicRef58353 \" href=\"mobipreview.htm?11/36/11842\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Despite these differences, the results of all three methods have a nearly linear relationship to each other and provide data of similar prognostic value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/2\">",
"     2",
"    </a>",
"    ]. Equivalent measurements for the three methods have been determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 50 percent stenosis with the NASCET method is comparable to a 65 percent stenosis for both the ECST and CC methods",
"     </li>",
"     <li>",
"      A 70 percent stenosis with the NASCET method is comparable to an 82 percent stenosis for both the ECST and CC methods",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CONVENTIONAL CEREBRAL ANGIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral angiography is the gold standard for imaging the carotid arteries. The development of intraarterial digital subtraction angiography (DSA) reduces the dose of contrast, uses smaller catheters, and shortens the length of the procedure. Although there is lower spatial resolution, DSA has largely replaced conventional angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The quality of the angiogram depends upon selective catheterization of the carotid artery with at least two unimpeded views. Aortic arch injections alone are inadequate; suboptimal studies can lead to misinterpretations as an irregular stenosis can be either underestimated or overestimated in a single projection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebral angiography permits an evaluation of the entire carotid artery system, providing information about tandem atherosclerotic disease, plaque morphology, and collateral circulation which may affect management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, the results from one study suggested that the presence of associated intracranial atherosclerotic disease identifies a group that is particularly likely to benefit from carotid endarterectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/9\">",
"     9",
"    </a>",
"    ]. However, pathologic evaluation of the plaque specimen provides the most useful data on plaque composition, which may have a bearing on prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disadvantages of angiography include its invasive nature, high cost, and risk of morbidity and mortality. In a review of prospective studies using cerebral angiography, the risk of all neurologic complications was approximately 4 percent and the risk of serious neurologic complications or death was approximately 1 percent (range 0 to 6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/7\">",
"     7",
"    </a>",
"    ]. The risk of morbidity is increased with cerebrovascular symptoms, advanced age, diabetes, hypertension, elevated serum creatinine, and peripheral vascular disease. The size of the catheter, amount of contrast, and procedure duration also affect the likelihood of complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/10\">",
"     10",
"    </a>",
"    ]. One study found that embolic events following angiography occur more frequently than the apparent neurologic complication rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/12\">",
"     12",
"    </a>",
"    ]; the clinical significance of this finding is unclear.",
"   </p>",
"   <p>",
"    Although often considered the \"gold standard\" of carotid neurovascular imaging methods, conventional DSA has the disadvantage of a limited number of projections, typically two or three, depicting the carotid artery and bifurcation. This limitation could lead to an underestimation of the degree of carotid stenosis in arteries that have asymmetrical rather than concentric stenotic lumens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Rotational angiography provides 16 to 32 projections and is far less subject to this problem, but it is seldom used in practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CAROTID DUPLEX ULTRASOUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid duplex ultrasound (CDUS) uses B-mode ultrasound imaging and Doppler ultrasound to detect focal increases in blood flow velocity indicative of high grade carotid stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. The peak systolic velocity is the most frequently used measurement to gauge the severity of the stenosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69525 \" href=\"mobipreview.htm?11/47/12019\">",
"     image 1",
"    </a>",
"    ), but the end-diastolic velocity, spectral configuration, and the carotid index (or peak internal carotid artery velocity to common carotid artery velocity ratio) provide additional information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Color Doppler flow imaging may improve the efficiency of the test, but it has not been shown to improve accuracy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/15,17,20,21\">",
"     15,17,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We examined the correlation between Doppler velocities and the residual lumen diameters of internal carotid arteries from surgical pathological specimens to establish Doppler criteria for residual lumen diameter, independent of the percent stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/22\">",
"     22",
"    </a>",
"    ]. Peak systolic velocity (PSV), end-diastolic velocity (EDV), and carotid index (peak internal carotid artery [ICA] velocity &divide; common carotid artery [CCA] velocity) correlated with the residual lumen diameter.",
"   </p>",
"   <p>",
"    By adjustment of velocity criteria, we found that CDUS can be either highly specific or highly sensitive for detecting a residual lumen diameter of &lt;1.5 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A specificity of 100 percent was found for PSV &gt;440",
"      <span class=\"nowrap\">",
"       cm/sec,",
"      </span>",
"      EDV &gt;155",
"      <span class=\"nowrap\">",
"       cm/sec,",
"      </span>",
"      or carotid index &gt;10. The sensitivity for these measures was 58 percent, 63 percent, and 30 percent, respectively. By combining these criteria, the sensitivity increased to 72 percent.",
"     </li>",
"     <li>",
"      A sensitivity of 96 percent was found for PSV &gt;200",
"      <span class=\"nowrap\">",
"       cm/sec",
"      </span>",
"      combined with either an EDV &gt;140",
"      <span class=\"nowrap\">",
"       cm/sec",
"      </span>",
"      or a carotid index &gt;4.5. The specificity for these combined measures was 61 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis published in 2006 concluded that CDUS compared with intraarterial cerebral angiography for the diagnosis of 70 to 99 percent carotid stenosis had a sensitivity of 0.89 (95% CI 0.85-0.92) and a specificity of 0.84 (95% CI 0.77-0.89) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/23\">",
"     23",
"    </a>",
"    ]. An earlier systematic review concluded that the sensitivity and specificity of CDUS compared with digital subtraction angiography for diagnosing complete carotid occlusion were 96 and 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The accuracy of CDUS relies heavily upon the experience and expertise of the ultrasonographer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/17,25\">",
"     17,25",
"    </a>",
"    ]. Measurement threshold properties may vary widely between laboratories, and the magnitude of the variation is clinically important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. There may be substantial variability in interpretation even when the same scanner and same criteria for carotid stenosis are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/25,28\">",
"     25,28",
"    </a>",
"    ]. Although important, it may be difficult for the clinician to know the accuracy of",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    local ultrasound laboratory. Accreditation by the multidisciplinary Intersocietal Commission for the Accreditation of Vascular Laboratories (ICAVL) assures that the ultrasound data meet certain criteria, including correlation against the gold standard of conventional angiography.",
"   </p>",
"   <p>",
"    CDUS has limited utility in obtaining information about plaque composition and intraplaque hemorrhage, which may increase the risk of embolism and impact on prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/11,15-17,29,30\">",
"     11,15-17,29,30",
"    </a>",
"    ]. In one study, patients with echolucent atherosclerotic plaques had a significantly increased risk of ischemic cerebrovascular events compared with patients with echogenic plaques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid duplex ultrasound (CDUS) is a noninvasive, safe, and relatively inexpensive technique for evaluation of the carotid arteries. It is 81 to 98 percent sensitive and 82 to 89 percent specific in detecting a significant stenosis of the internal carotid artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/15-17,32\">",
"     15-17,32",
"    </a>",
"    ]. Data based upon the NASCET method of calculating angiographic stenosis showed that a carotid index (peak internal carotid artery velocity &divide; common carotid artery velocity) &gt;4 provided the highest accuracy (sensitivity 91 percent, specificity 87 percent, overall accuracy 88 percent) for predicting a high grade stenosis (70 to 99 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using published outcome data and receiver operator characteristic analysis, test criteria can be developed that maximize patient outcome for a specific clinical scenario [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/34\">",
"     34",
"    </a>",
"    ]. As discussed below, the positive predictive value of CDUS for identifying appropriate asymptomatic candidates for carotid intervention may be lower in community hospitals and centers without a certified vascular laboratory. We suggest that high grade carotid stenosis should be confirmed by both anatomic (eg, MRA, CTA, conventional angiography) and physiologic (CDUS) imaging before intervention, with CDUS performed in an accredited vascular laboratory. However, other experts disagree about the need for additional imaging, and carotid revascularization is performed in many centers using CDUS as the sole preoperative imaging modality for the cervical carotid artery in asymptomatic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absence of flow in the internal carotid artery may be due to occlusion, but hairline residual lumens can be missed on carotid duplex ultrasound (CDUS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, several studies have found that CDUS tends to overestimate the degree of stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/32,37\">",
"     32,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CDUS is less precise in determining stenoses of &lt;50 percent compared with stenoses of higher degrees [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, this rarely impacts on its clinical utility as intervention is not indicated for any condition associated with internal carotid artery stenosis at the bifurcation of &lt;50 percent. CDUS may also be less accurate in determining stenoses in the range of 50 to 69 percent compared with &ge;70 percent stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/32\">",
"     32",
"    </a>",
"    ]. However, this too rarely impacts on its clinical utility because most patients with asymptomatic carotid stenosis who are considered for endarterectomy have &ge;70 percent stenosis. In addition, while patients with relevant symptoms and 50 to 69 percent stenosis may be appropriate for carotid intervention, the majority of patients with symptomatic internal carotid artery stenosis have &ge;70 percent stenosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/33/16922?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of asymptomatic carotid atherosclerotic disease\", section on 'Carotid endarterectomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21530?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of symptomatic carotid atherosclerotic disease\", section on 'Carotid endarterectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CDUS imaging may be limited by features such as calcific carotid lesions, tortuous or kinked carotid arteries, and patient body habitus. Furthermore, CDUS must be interpreted carefully in patients with contralateral carotid occlusion to avoid overestimation of an ipsilateral carotid stenosis, since the peak systolic velocity is often increased in the presence of a contralateral internal carotid occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/38\">",
"     38",
"    </a>",
"    ]. Another limitation of CDUS is that only the cervical portion of the internal carotid artery can be evaluated, although transcranial Doppler may provide some information about intracranial vessels. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Transcranial Doppler'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The limitations of CDUS are illustrated in studies from community-based centers showing that performing carotid endarterectomy on the basis of CDUS alone would result in a significant number of unnecessary surgeries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. This problem likely reflects the high variability of laboratory quality at many community-based centers. The need for laboratory accreditation and quality assurance cannot be overstated. In addition, community health screening services use an abbreviated ultrasound examination. Patients identified by these as having a high-grade carotid stenosis should be assessed with a complete CDUS evaluation in an accredited vascular laboratory. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/27/40378?source=see_link&amp;anchor=H83592233#H83592233\">",
"     \"Carotid endarterectomy\", section on 'Other imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TRANSCRANIAL DOPPLER",
"    </span>",
"    &nbsp;&mdash;&nbsp;As an adjunct to carotid Doppler ultrasound (CDUS), transcranial Doppler (TCD) examines the major intracerebral arteries through the orbit and at the base of the brain. TCD is often used in conjunction with CDUS to evaluate the hemodynamic significance of internal carotid artery (ICA) stenosis, and it can be used to improve the accuracy of CDUS in identifying surgical carotid disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TCD can evaluate the intracranial hemodynamic consequences of high grade carotid lesions, such as the development of collateral flow patterns in the circle of Willis, reversal of flow in the ophthalmic and anterior cerebral arteries, absence of ophthalmic or carotid siphon flow, and reduced MCA flow velocity and pulsatility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An assessment of TCD by the American Academy of Neurology (AAN) concluded that TCD is possibly useful for the evaluation of severe extracranial ICA stenosis or occlusion, but in general CDUS and MRA are the tests of choice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/44\">",
"     44",
"    </a>",
"    ]. The AAN report noted that the clinical utility of TCD to detect impaired cerebral hemodynamics distal to high grade extracranial ICA stenosis or occlusion and assist with stroke risk assessment requires evaluation and confirmation in randomized clinical trials.",
"   </p>",
"   <p>",
"    We examined the sensitivity and specificity of TCD criteria in detecting a hemodynamically significant stenosis (residual lumen diameter &lt;1.5 mm) at the origin of the ICA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the transorbital approach, the strongest indicators of a residual lumen diameter &lt;1.5 mm were reversed flow in the ipsilateral ophthalmic artery and a &gt;50 percent peak systolic velocity difference between the carotid siphons (distal internal carotid arteries) in patients with unilateral internal carotid artery origin stenosis. These findings were 100 percent specific and 31 percent and 26 percent sensitive respectively.",
"     </li>",
"     <li>",
"      For the transtemporal approach in patients with a unilateral stenosis, a &gt;35 percent difference in ipsilateral middle cerebral artery peak systolic velocity relative to the contralateral middle cerebral artery, or a &gt;50 percent difference in contralateral anterior cerebral artery peak systolic velocity relative to the ipsilateral anterior cerebral artery were 100 percent specific for identifying a residual lumen diameter of &lt;1.5 mm. Sensitivities were 32 percent and 43 percent respectively. Regardless of contralateral stenosis, a &gt;35 percent difference in ipsilateral middle cerebral artery peak systolic velocity relative to the ipsilateral posterior cerebral artery had a 100 percent specificity and a 23 percent sensitivity for detecting a &lt;1.5 mm minimal residual lumen diameter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    TCD can also be used for detection of middle cerebral artery microemboli that arise from the heart or carotid artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/46\">",
"     46",
"    </a>",
"    ]. These are visualized as high intensity signal transients (HITS) within the Doppler spectrum. Mounting evidence from observational studies suggests that asymptomatic cerebral embolism detected by TCD is associated with an increased risk of ischemic stroke in patients with asymptomatic carotid atherosclerotic occlusive disease. This issue is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/33/16922?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of asymptomatic carotid atherosclerotic disease\", section on 'Asymptomatic embolism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ADDITIONAL ULTRASOUND MODALITIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newer modalities such as contrast enhanced ultrasound, 3-dimensional ultrasound, and compound B-mode ultrasound may offer improved carotid plaque imaging compared with CDUS. If so, they may provide a means of assaying carotid plaque features that are markers for different stages and phenotypes of atherosclerosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H169797247\">",
"    <span class=\"h2\">",
"     Contrast enhanced ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast enhanced ultrasound is performed after intravenous injection of a microbubble contrast agent. This technique may be useful for evaluating carotid plaque neovascularization, a possible marker of plaque instability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. In addition, contrast enhanced ultrasound may help distinguish complete carotid occlusion from near occlusion and improve lumen visualization in carotid arteries that are technically challenging to study by conventional carotid duplex ultrasonography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     3D ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three dimensional (3D) ultrasound improves visualization of vascular anatomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/50\">",
"     50",
"    </a>",
"    ]. Advantages compared with B-mode ultrasound include the potential for quantitative monitoring of plaque volume changes in all three directions (circumferentially as well as length and thickness) rather than one or two directions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/51\">",
"     51",
"    </a>",
"    ]. This in turn could allow measurement of plaque volume change, which may be a more sensitive marker of plaque progression than measurements of plaque area, intima-media thickness, and carotid stenosis.",
"   </p>",
"   <p>",
"    Disadvantages of 3D ultrasound include a tendency for underestimation of vessel stenosis and difficulty imaging areas of calcification [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/52\">",
"     52",
"    </a>",
"    ]. It is also not widely available or utilized in routine clinical care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Compound ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compound ultrasound utilizes a technique called compounding to average several images taken from different perspectives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/53\">",
"     53",
"    </a>",
"    ]. Advantages compared with B-mode ultrasound include improved visualization of plaque texture and surface, as well as reduction of artifacts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/54\">",
"     54",
"    </a>",
"    ]. In addition, reproducibility in the evaluation of plaque morphology appears to be good, and interobserver agreement of plaque echogenicity is higher than with B-mode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/54\">",
"     54",
"    </a>",
"    ]. Advances in computational power have made real time compound imaging available for clinical practice, but is not widely utilized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MR ANGIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The magnetic resonance angiography (MRA) techniques most often employed for evaluating the extracranial carotid arteries utilize either two or three dimensional time-of-flight (TOF) MRA or gadolinium-enhanced MRA (also known as contrast enhanced MRA or CEMRA). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5689?source=see_link\">",
"     \"Principles of magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MRA produces a reproducible three dimensional image of the carotid bifurcation with good sensitivity for detecting high grade carotid stenosis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79993 \" href=\"mobipreview.htm?9/15/9470\">",
"     image 2",
"    </a>",
"    ). In earlier studies, MRA was found to generally overestimate the degree and length of stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/16,55\">",
"     16,55",
"    </a>",
"    ]. However, a later study of three dimensional TOF MRA found that it did not overestimate the degree of stenosis when corresponding MRA and digital subtraction angiography (DSA) projections were compared [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Contrast enhanced magnetic resonance angiography (CEMRA) offers several advantages over traditional TOF techniques. The use of a paramagnetic agent acting as a vascular contrast allows for higher quality images that are less prone to artifacts.",
"   </p>",
"   <p>",
"    Both TOF MRA and CEMRA are accurate for the identification of high-grade carotid artery stenosis and occlusion, but appear to be less accurate for detecting moderate stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/57\">",
"     57",
"    </a>",
"    ]. The sensitivities of either MRA technique for the identification of carotid artery occlusion or severe stenosis were similar and ranged from 91 to 99 percent, while specificities ranged from 88 to 99 percent.",
"   </p>",
"   <p>",
"    Compared with carotid duplex ultrasound, MRA is less operator-dependent and does produce an image of the artery. However, MRA is more expensive and time-consuming than carotid duplex ultrasound and is less readily available. Furthermore, MRA may not be performed if the patient is critically ill, unable to lie supine, or has claustrophobia, a pacemaker or ferromagnetic implants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/16\">",
"     16",
"    </a>",
"    ]. In different series, up to 17 percent of MRA studies are incomplete because the patient could not tolerate the study or could not lie still enough to produce an image of adequate quality for interpretation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/58\">",
"     58",
"    </a>",
"    ]. Renal insufficiency is a relative contraindication to the use of gadolinium.",
"   </p>",
"   <p>",
"    Advanced magnetic resonance imaging techniques are being studied to assess whether changes in carotid plaque characteristics &ndash; such as rupture of fibrous cap and intraplaque hemorrhage &ndash; are reliably associated with an increased risk of subsequent stroke in patients with asymptomatic carotid atherosclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/24/9608?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathophysiology of symptoms from carotid atherosclerosis\", section on 'Plaque morphology and pathology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     CT ANGIOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography angiography (CTA) provides an anatomic depiction of the carotid artery lumen and allows imaging of adjacent soft tissue and bony structures. Three dimensional reconstruction allows relatively accurate measurements of residual lumen diameter. CTA may be particularly useful when carotid duplex ultrasound is not reliable (eg, in cases with severe kinking, severe calcification, short neck, or high bifurcation) or when an overall view of the vascular field is required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis published in 2006 concluded that CTA compared with intraarterial cerebral angiography for the diagnosis of 70 to 99 percent carotid stenosis had a sensitivity of 0.77 (95% CI 0.68-0.84) and a specificity of 0.95 (95% CI 0.91-0.97) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An earlier systematic review and meta-analysis that compared CTA with arteriography or digital subtraction angiography concluded that CTA is an accurate method for detection of severe carotid artery disease, particularly for detection of carotid occlusion, where CTA had a sensitivity and specificity of 97 and 99 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CT angiography requires a contrast bolus comparable to that administered during a conventional angiogram. As a result, impaired renal function is a relative contraindication for its use, particularly in patients with diabetes or congestive heart failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF COMPLETE OCCLUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;No surgical treatment has been proven to be of benefit for preventing a subsequent stroke in patients with complete carotid artery occlusion. Thus, it is important to adequately distinguish between completely occluded vessels and those with some remaining flow since the latter group may benefit from carotid revascularization.",
"   </p>",
"   <p>",
"    In earlier reports, magnetic resonance angiography (MRA) and carotid duplex ultrasound (CDUS) both had difficulties distinguishing very severe stenosis from occlusion. False-positive and false-negative results occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Combined techniques of 3D and 2D time of flight seemed to improve the performance of MRA but were not routinely employed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/16,55,66,67\">",
"     16,55,66,67",
"    </a>",
"    ]. However, later studies indicated that improved recognition of near and total occlusion is possible with CDUS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/24\">",
"     24",
"    </a>",
"    ] and MRA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/24,68\">",
"     24,68",
"    </a>",
"    ]. In addition, one report found that computed tomography angiography (CTA) was 100 percent sensitive and specific for detection of near and total carotid occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, in current practice the combination of MRA and CDUS is probably sufficient for identifying patients with carotid artery occlusion. This was illustrated in a study of 274 patients in whom angiography identified 37 total and 21 near occlusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/70\">",
"     70",
"    </a>",
"    ]. Ultrasound adequately identified all angiographically determined total occlusions, but 3 of 21 near occlusions (14 percent) were reported as totally occluded on ultrasound, and one of the three patients was a candidate for carotid endarterectomy. MRA correctly identified 34 of 37 near total occlusions (92 percent) and all total occlusions. The authors concluded that no further imaging is necessary when complete occlusion is suspected on the basis of an initial CDUS study and confirmed on MRA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CHOICE OF IMAGING TEST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional cerebral angiography has been considered the gold standard for the evaluation of internal carotid artery stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/71\">",
"     71",
"    </a>",
"    ]. However, angiography is associated with a small but real risk of stroke, which makes it ill suited for use as a screening test. In addition, most patients with ischemic symptoms referable to the carotid vascular territory do not have severe carotid stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. In one series of 261 patients with carotid territory ischemic strokes and 813 patients with carotid territory TIA, carotid disease was absent in 55 and 64 percent, respectively (and in 69 and 77 percent of those without a carotid bruit) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result, patients are generally selected for angiography using one of the noninvasive tests:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Carotid duplex ultrasonography (CDUS)",
"     </li>",
"     <li>",
"      Time of flight magnetic resonance angiography (TOF MRA)",
"     </li>",
"     <li>",
"      Contrast enhanced magnetic resonance angiography (CEMRA)",
"     </li>",
"     <li>",
"      Computed tomography angiography (CTA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These noninvasive tests have essentially replaced conventional cerebral angiography in the presurgical evaluation of carotid stenosis. The choice among the noninvasive carotid artery imaging methods depends mainly upon the clinical indications for imaging and the availability and expertise at individual centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis of 41 studies and 2541 patients published in 2006 that assessed different noninvasive imaging methods, the following observations were made [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CDUS, MRA, CEMRA, and CTA all have high sensitivities and specificities for diagnosing 70 to 99 percent internal carotid artery stenosis in patients with ipsilateral carotid territory ischemic symptoms.",
"     </li>",
"     <li>",
"      CEMRA may be marginally more accurate than the other noninvasive methods, but this technique is relatively new and the published studies included in the meta-analysis came from research environments as opposed to routine clinical practice environments.",
"     </li>",
"     <li>",
"      The accuracy of the noninvasive tests for 50 to 69 percent carotid stenosis appears to be substantially reduced compared with 79 to 99 percent stenosis. However, the data are sparse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The combination of carotid ultrasound and MRA may obviate the need for conventional angiography in the presurgical assessment of patients with carotid artery disease, particularly when the tests agree [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/37,75,76\">",
"     37,75,76",
"    </a>",
"    ]. Some have reported that the combination of ultrasound and MRA is cost-effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/77,78\">",
"     77,78",
"    </a>",
"    ] and results in an overall error rate that is comparable to the interobserver reliability when two radiologists are presented with the same conventional angiogram revealing carotid artery disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/79\">",
"     79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/27/40378?source=see_link\">",
"     \"Carotid endarterectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bypassing angiography before surgery requires that noninvasive tests be highly specific as well as sensitive. TCD may be beneficial in this setting, increasing the specificity of carotid duplex ultrasound in detecting a &lt;1.5 mm residual lumen diameter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our general approach to patients with suspected carotid stenosis is to first perform CDUS. Those with stenosis &lt;50 percent are followed with serial examinations, usually on an annual basis, to determine if there is progression. Those with stenosis &ge;50 percent are evaluated with transcranial Doppler examination and MRA. CTA is performed in lieu of MRA if there is a contraindication to magnetic resonance imaging and in cases where the CDUS and MRA do not agree. We believe this approach provides optimal care and likely avoids unnecessary carotid revascularization procedures with endarterectomy and stenting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. However, there is no consensus regarding the optimal imaging evaluations for patients with asymptomatic carotid stenosis detected by ultrasound. Some experts are not persuaded by the limited data suggesting improved outcomes for patients who undergo additional imaging modalities, and question whether additional imaging in asymptomatic patients might actually increase the risk of unneeded interventions in addition to increasing the cost. As noted earlier, many centers rely on a single noninvasive imaging test (most often CDUS) for preprocedural carotid artery evaluation and for serial evaluation of patients with asymptomatic high-grade carotid stenosis.",
"   </p>",
"   <p>",
"    Conventional angiography is rarely performed; indications include patients who cannot tolerate an MRA and in whom the risk of dye is sufficient to warrant bypassing CTA in favor of the gold standard examination. Angiography is also done if nonatherosclerotic disease is suspected (eg, dissection, vasculitis). Other potential reasons for conventional catheter cerebral angiography include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31033/abstract/74\">",
"     74",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suspected disease affecting the proximal common carotid artery or the origins of the great vessels from the aortic arch",
"     </li>",
"     <li>",
"      Severe multi-vessel disease, such as combined carotid and vertebral artery disease, for which assessment of blood flow direction and collateral patterns may be informative; however, this information can usually be established using noninvasive methods, and is of questionable value for patients who are asymptomatic",
"     </li>",
"     <li>",
"      Poor quality of noninvasive imaging",
"     </li>",
"     <li>",
"      Discordant results of noninvasive imaging",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/14/12512?source=see_link\">",
"       \"Patient information: Carotid artery disease (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/55/24435?source=see_link\">",
"       \"Patient information: Stroke (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/34/30242?source=see_link\">",
"       \"Patient information: Doppler ultrasound (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/37/38484?source=see_link\">",
"       \"Patient information: Stroke symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85865907\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three methods of carotid stenosis measurement (NASCET, ECST, and CC) predominate worldwide. Although all three were originally devised for use with conventional contrast angiography, these methods can also be used with magnetic resonance and computed tomography angiography. The results of all three methods have a nearly linear relationship to each other and provide data of similar prognostic value. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Stenosis measurement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cerebral angiography is the gold standard for imaging the carotid arteries. The development of intraarterial digital subtraction angiography (DSA) reduces the dose of contrast, uses smaller catheters, and shortens the length of the procedure. Nevertheless, the use of intraarterial cerebral angiography is limited by its invasive nature, high cost, and risk of morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Conventional cerebral angiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Carotid duplex ultrasound (CDUS) uses B-mode ultrasound imaging and Doppler ultrasound to detect focal increases in blood flow velocity indicative of high grade carotid stenosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef69525 \" href=\"mobipreview.htm?11/47/12019\">",
"       image 1",
"      </a>",
"      ). It is noninvasive, safe, and relatively inexpensive. Compared with intraarterial cerebral angiography for detecting a significant stenosis of the internal carotid artery, CDUS has a sensitivity of 81 to 98 percent and a specificity of 82 to 89 percent. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Carotid duplex ultrasound'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transcranial Doppler (TCD) examines the major intracerebral arteries through the orbit and at the base of the brain. TCD is often used in conjunction with CDUS to evaluate the hemodynamic significance of internal carotid artery stenosis, and it can be used to improve the accuracy of CDUS in identifying hemodynamically significant carotid disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Transcranial Doppler'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The magnetic resonance angiography (MRA) techniques most often employed for evaluating the extracranial carotid arteries utilize either two or three dimensional time-of-flight MRA or gadolinium-enhanced MRA (contrast enhanced MRA or CEMRA). MRA produces a reproducible three dimensional image of the carotid bifurcation with good sensitivity for detecting high grade carotid stenosis (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79993 \" href=\"mobipreview.htm?9/15/9470\">",
"       image 2",
"      </a>",
"      ). Both time-of-flight MRA and CEMRA are accurate for the identification of high-grade carotid artery stenosis and occlusion. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'MR angiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Computed tomography angiography (CTA) provides an anatomic depiction of the carotid artery lumen and allows imaging of adjacent soft tissue and bony structures. Three dimensional reconstruction allows relatively accurate measurements of residual lumen diameter. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'CT angiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because of the invasive nature and risks associated with conventional intraarterial catheter angiography, most patients are evaluated for carotid disease using one of the noninvasive tests (CDUS, time-of-flight MRA, CEMRA, or CTA). These noninvasive imaging modalities all have high sensitivities and specificities for diagnosing 70 to 99 percent internal carotid artery stenosis in patients with ipsilateral carotid territory ischemic symptoms. The accuracy of the noninvasive tests for 50 to 69 percent carotid stenosis appears to be substantially reduced compared with 79 to 99 percent stenosis. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Choice of imaging test'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23478449\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Janet Wilterdink and Dr. Philip Kistler for their contributions to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/1\">",
"      Toole JF, Castaldo JE. Accurate measurement of carotid stenosis. Chaos in methodology. J Neuroimaging 1994; 4:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/2\">",
"      Rothwell PM, Gibson RJ, Slattery J, et al. Equivalence of measurements of carotid stenosis. A comparison of three methods on 1001 angiograms. European Carotid Surgery Trialists' Collaborative Group. Stroke 1994; 25:2435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/3\">",
"      North American Symptomatic Carotid Endarterectomy Trial. Methods, patient characteristics, and progress. Stroke 1991; 22:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/4\">",
"      MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. European Carotid Surgery Trialists' Collaborative Group. Lancet 1991; 337:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/5\">",
"      Wardlaw JM, Lewis SC, Humphrey P, et al. How does the degree of carotid stenosis affect the accuracy and interobserver variability of magnetic resonance angiography? J Neurol Neurosurg Psychiatry 2001; 71:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/6\">",
"      Rothwell PM, Eliasziw M, Gutnikov SA, et al. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet 2003; 361:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/7\">",
"      Hankey GJ, Warlow CP, Sellar RJ. Cerebral angiographic risk in mild cerebrovascular disease. Stroke 1990; 21:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/8\">",
"      Wolpert SM, Caplan LR. Current role of cerebral angiography in the diagnosis of cerebrovascular diseases. AJR Am J Roentgenol 1992; 159:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/9\">",
"      Kappelle LJ, Eliasziw M, Fox AJ, et al. Importance of intracranial atherosclerotic disease in patients with symptomatic stenosis of the internal carotid artery. The North American Symptomatic Carotid Endarterectomy Trail. Stroke 1999; 30:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/10\">",
"      Edwards JH, Kricheff II, Riles T, Imparato A. Angiographically undetected ulceration of the carotid bifurcation as a cause of embolic stroke. Radiology 1979; 132:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/11\">",
"      O'Donnell TF Jr, Erdoes L, Mackey WC, et al. Correlation of B-mode ultrasound imaging and arteriography with pathologic findings at carotid endarterectomy. Arch Surg 1985; 120:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/12\">",
"      Bendszus M, Koltzenburg M, Burger R, et al. Silent embolism in diagnostic cerebral angiography and neurointerventional procedures: a prospective study. Lancet 1999; 354:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/13\">",
"      Bosanac Z, Miller RJ, Jain M. Rotational digital subtraction carotid angiography: technique and comparison with static digital subtraction angiography. Clin Radiol 1998; 53:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/14\">",
"      Elgersma OE, Buijs PC, W&uuml;st AF, et al. Maximum internal carotid arterial stenosis: assessment with rotational angiography versus conventional intraarterial digital subtraction angiography. Radiology 1999; 213:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/15\">",
"      Carroll BA. Carotid sonography. Radiology 1991; 178:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/16\">",
"      Tsuruda JS, Saloner D, Anderson C. Noninvasive evaluation of cerebral ischemia. Trends for the 1990s. Circulation 1991; 83:I176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/17\">",
"      Zwiebel WJ. Duplex sonography of the cerebral arteries: efficacy, limitations, and indications. AJR Am J Roentgenol 1992; 158:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/18\">",
"      Hunink MG, Polak JF, Barlan MM, O'Leary DH. Detection and quantification of carotid artery stenosis: efficacy of various Doppler velocity parameters. AJR Am J Roentgenol 1993; 160:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/19\">",
"      Huston J 3rd, James EM, Brown RD Jr, et al. Redefined duplex ultrasonographic criteria for diagnosis of carotid artery stenosis. Mayo Clin Proc 2000; 75:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/20\">",
"      Hallam MJ, Reid JM, Cooperberg PL. Color-flow Doppler and conventional duplex scanning of the carotid bifurcation: prospective, double-blind, correlative study. AJR Am J Roentgenol 1989; 152:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/21\">",
"      Steinke W, Kloetzsch C, Hennerici M. Carotid artery disease assessed by color Doppler flow imaging: correlation with standard Doppler sonography and angiography. AJR Am J Roentgenol 1990; 154:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/22\">",
"      Suwanwela N, Can U, Furie KL, et al. Carotid Doppler ultrasound criteria for internal carotid artery stenosis based on residual lumen diameter calculated from en bloc carotid endarterectomy specimens. Stroke 1996; 27:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/23\">",
"      Wardlaw JM, Chappell FM, Best JJ, et al. Non-invasive imaging compared with intra-arterial angiography in the diagnosis of symptomatic carotid stenosis: a meta-analysis. Lancet 2006; 367:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/24\">",
"      Nederkoorn PJ, van der Graaf Y, Hunink MG. Duplex ultrasound and magnetic resonance angiography compared with digital subtraction angiography in carotid artery stenosis: a systematic review. Stroke 2003; 34:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/25\">",
"      Criswell BK, Langsfeld M, Tullis MJ, Marek J. Evaluating institutional variability of duplex scanning in the detection of carotid artery stenosis. Am J Surg 1998; 176:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/26\">",
"      Jahromi AS, Cin&agrave; CS, Liu Y, Clase CM. Sensitivity and specificity of color duplex ultrasound measurement in the estimation of internal carotid artery stenosis: a systematic review and meta-analysis. J Vasc Surg 2005; 41:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/27\">",
"      Beach KW, Leotta DF, Zierler RE. Carotid Doppler velocity measurements and anatomic stenosis: correlation is futile. Vasc Endovascular Surg 2012; 46:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/28\">",
"      Corriveau MM, Johnston KW. Interobserver variability of carotid Doppler peak velocity measurements among technologists in an ICAVL-accredited vascular laboratory. J Vasc Surg 2004; 39:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/29\">",
"      Ammar AD, Mullins JR. Incidence of bilateral intraplaque hemorrhage in carotid artery disease. Cardiovasc Surg 1993; 1:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/30\">",
"      Langsfeld M, Gray-Weale AC, Lusby RJ. The role of plaque morphology and diameter reduction in the development of new symptoms in asymptomatic carotid arteries. J Vasc Surg 1989; 9:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/31\">",
"      Mathiesen EB, B&oslash;naa KH, Joakimsen O. Echolucent plaques are associated with high risk of ischemic cerebrovascular events in carotid stenosis: the troms&oslash; study. Circulation 2001; 103:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/32\">",
"      Sabeti S, Schillinger M, Mlekusch W, et al. Quantification of internal carotid artery stenosis with duplex US: comparative analysis of different flow velocity criteria. Radiology 2004; 232:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/33\">",
"      Moneta GL, Edwards JM, Chitwood RW, et al. Correlation of North American Symptomatic Carotid Endarterectomy Trial (NASCET) angiographic definition of 70% to 99% internal carotid artery stenosis with duplex scanning. J Vasc Surg 1993; 17:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/34\">",
"      Wilterdink JL, Feldmann E, Easton JD, Ward R. Performance of carotid ultrasound in evaluating candidates for carotid endarterectomy is optimized by an approach based on clinical outcome rather than accuracy. Stroke 1996; 27:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/35\">",
"      Grant EG, Benson CB, Moneta GL, et al. Carotid artery stenosis: gray-scale and Doppler US diagnosis--Society of Radiologists in Ultrasound Consensus Conference. Radiology 2003; 229:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/36\">",
"      Dawson DL, Zierler RE, Strandness DE Jr, et al. The role of duplex scanning and arteriography before carotid endarterectomy: a prospective study. J Vasc Surg 1993; 18:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/37\">",
"      Nederkoorn PJ, Mali WP, Eikelboom BC, et al. Preoperative diagnosis of carotid artery stenosis: accuracy of noninvasive testing. Stroke 2002; 33:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/38\">",
"      Fujitani RM, Mills JL, Wang LM, Taylor SM. The effect of unilateral internal carotid arterial occlusion upon contralateral duplex study: criteria for accurate interpretation. J Vasc Surg 1992; 16:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/39\">",
"      Johnston DC, Goldstein LB. Clinical carotid endarterectomy decision making: noninvasive vascular imaging versus angiography. Neurology 2001; 56:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/40\">",
"      Qureshi AI, Suri MF, Ali Z, et al. Role of conventional angiography in evaluation of patients with carotid artery stenosis demonstrated by Doppler ultrasound in general practice. Stroke 2001; 32:2287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/41\">",
"      Wilterdink JL, Furie KL, Benavides J, et al. Combined transcranial and carotid Duplex ultrasound optimizes screening for carotid artery stenosis. Can J Neurol Sci 1993; 20:S205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/42\">",
"      Wilterdink JL, Feldmann E, Furie KL, et al. Transcranial Doppler ultrasound battery reliably identifies severe internal carotid artery stenosis. Stroke 1997; 28:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/43\">",
"      Molina CA, Montaner J, Abilleira S, et al. Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke. Stroke 2001; 32:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/44\">",
"      Sloan MA, Alexandrov AV, Tegeler CH, et al. Assessment: transcranial Doppler ultrasonography: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2004; 62:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/45\">",
"      Can U, Furie KL, Suwanwela N, et al. Transcranial Doppler ultrasound criteria for hemodynamically significant internal carotid artery stenosis based on residual lumen diameter calculated from en bloc endarterectomy specimens. Stroke 1997; 28:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/46\">",
"      Siebler M, Kleinschmidt A, Sitzer M, et al. Cerebral microembolism in symptomatic and asymptomatic high-grade internal carotid artery stenosis. Neurology 1994; 44:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/47\">",
"      Partovi S, Loebe M, Aschwanden M, et al. Contrast-enhanced ultrasound for assessing carotid atherosclerotic plaque lesions. AJR Am J Roentgenol 2012; 198:W13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/48\">",
"      Staub D, Schinkel AF, Coll B, et al. Contrast-enhanced ultrasound imaging of the vasa vasorum: from early atherosclerosis to the identification of unstable plaques. JACC Cardiovasc Imaging 2010; 3:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/49\">",
"      Ten Kate GL, van den Oord SC, Sijbrands EJ, et al. Current status and future developments of contrast-enhanced ultrasound of carotid atherosclerosis. J Vasc Surg 2013; 57:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/50\">",
"      Fenster A, Downey DB, Cardinal HN. Three-dimensional ultrasound imaging. Phys Med Biol 2001; 46:R67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/51\">",
"      Landry A, Spence JD, Fenster A. Measurement of carotid plaque volume by 3-dimensional ultrasound. Stroke 2004; 35:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/52\">",
"      Wessels T, Harrer JU, Stetter S, et al. Three-dimensional assessment of extracranial Doppler sonography in carotid artery stenosis compared with digital subtraction angiography. Stroke 2004; 35:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/53\">",
"      Jespersen SK, Wilhjelm JE, Sillesen H. Multi-angle compound imaging. Ultrason Imaging 1998; 20:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/54\">",
"      Kern R, Szabo K, Hennerici M, Meairs S. Characterization of carotid artery plaques using real-time compound B-mode ultrasound. Stroke 2004; 35:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/55\">",
"      Bowen BC, Quencer RM, Margosian P, Pattany PM. MR angiography of occlusive disease of the arteries in the head and neck: current concepts. AJR Am J Roentgenol 1994; 162:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/56\">",
"      Nederkoorn PJ, Elgersma OE, Mali WP, et al. Overestimation of carotid artery stenosis with magnetic resonance angiography compared with digital subtraction angiography. J Vasc Surg 2002; 36:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/57\">",
"      Debrey SM, Yu H, Lynch JK, et al. Diagnostic accuracy of magnetic resonance angiography for internal carotid artery disease: a systematic review and meta-analysis. Stroke 2008; 39:2237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/58\">",
"      Sitzer M, F&uuml;rst G, Fischer H, et al. Between-method correlation in quantifying internal carotid stenosis. Stroke 1993; 24:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/59\">",
"      Takaya N, Yuan C, Chu B, et al. Association between carotid plaque characteristics and subsequent ischemic cerebrovascular events: a prospective assessment with MRI--initial results. Stroke 2006; 37:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/60\">",
"      Watanabe Y, Nagayama M. MR plaque imaging of the carotid artery. Neuroradiology 2010; 52:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/61\">",
"      Wasserman BA. Advanced contrast-enhanced MRI for looking beyond the lumen to predict stroke: building a risk profile for carotid plaque. Stroke 2010; 41:S12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/62\">",
"      Corti R, Ferrari C, Roberti M, et al. Spiral computed tomography: a novel diagnostic approach for investigation of the extracranial cerebral arteries and its complementary role in duplex ultrasonography. Circulation 1998; 98:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/63\">",
"      Koelemay MJ, Nederkoorn PJ, Reitsma JB, Majoie CB. Systematic review of computed tomographic angiography for assessment of carotid artery disease. Stroke 2004; 35:2306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/64\">",
"      Mattle HP, Kent KC, Edelman RR, et al. Evaluation of the extracranial carotid arteries: correlation of magnetic resonance angiography, duplex ultrasonography, and conventional angiography. J Vasc Surg 1991; 13:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/65\">",
"      Riles TS, Eidelman EM, Litt AW, et al. Comparison of magnetic resonance angiography, conventional angiography, and duplex scanning. Stroke 1992; 23:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/66\">",
"      Atlas SW. MR angiography in neurologic disease. Radiology 1994; 193:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/67\">",
"      Fisher M, Sotak CH, Minematsu K, Li L. New magnetic resonance techniques for evaluating cerebrovascular disease. Ann Neurol 1992; 32:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/68\">",
"      Remonda L, Heid O, Schroth G. Carotid artery stenosis, occlusion, and pseudo-occlusion: first-pass, gadolinium-enhanced, three-dimensional MR angiography--preliminary study. Radiology 1998; 209:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/69\">",
"      Chen CJ, Lee TH, Hsu HL, et al. Multi-Slice CT angiography in diagnosing total versus near occlusions of the internal carotid artery: comparison with catheter angiography. Stroke 2004; 35:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/70\">",
"      El-Saden SM, Grant EG, Hathout GM, et al. Imaging of the internal carotid artery: the dilemma of total versus near total occlusion. Radiology 2001; 221:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/71\">",
"      Rothwell PM. For severe carotid stenosis found on ultrasound, further arterial evaluation prior to carotid endarterectomy is unnecessary: the argument against. Stroke 2003; 34:1817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/72\">",
"      Hankey GJ, Warlow CP. Symptomatic carotid ischaemic events: safest and most cost effective way of selecting patients for angiography, before carotid endarterectomy. BMJ 1990; 300:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/73\">",
"      Zhu CZ, Norris JW. Role of carotid stenosis in ischemic stroke. Stroke 1990; 21:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/74\">",
"      Jaff MR, Goldmakher GV, Lev MH, Romero JM. Imaging of the carotid arteries: the role of duplex ultrasonography, magnetic resonance arteriography, and computerized tomographic arteriography. Vasc Med 2008; 13:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/75\">",
"      Turnipseed WD, Kennell TW, Turski PA, et al. Combined use of duplex imaging and magnetic resonance angiography for evaluation of patients with symptomatic ipsilateral high-grade carotid stenosis. J Vasc Surg 1993; 17:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/76\">",
"      Polak JF, Kalina P, Donaldson MC, et al. Carotid endarterectomy: preoperative evaluation of candidates with combined Doppler sonography and MR angiography. Work in progress. Radiology 1993; 186:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/77\">",
"      Kent KC, Kuntz KM, Patel MR, et al. Perioperative imaging strategies for carotid endarterectomy. An analysis of morbidity and cost-effectiveness in symptomatic patients. JAMA 1995; 274:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/78\">",
"      U-King-Im JM, Hollingworth W, Trivedi RA, et al. Cost-effectiveness of diagnostic strategies prior to carotid endarterectomy. Ann Neurol 2005; 58:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31033/abstract/79\">",
"      Young GR, Sandercock PA, Slattery J, et al. Observer variation in the interpretation of intra-arterial angiograms and the risk of inappropriate decisions about carotid endarterectomy. J Neurol Neurosurg Psychiatry 1996; 60:152.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1118 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-42B5A9483A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_19_31033=[""].join("\n");
var outline_f30_19_31033=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H85865907\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STENOSIS MEASUREMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CONVENTIONAL CEREBRAL ANGIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Disadvantages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CAROTID DUPLEX ULTRASOUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Disadvantages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TRANSCRANIAL DOPPLER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ADDITIONAL ULTRASOUND MODALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H169797247\">",
"      Contrast enhanced ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      3D ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Compound ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MR ANGIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      CT ANGIOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIAGNOSIS OF COMPLETE OCCLUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CHOICE OF IMAGING TEST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H85865907\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23478449\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1118\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1118|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/47/12019\" title=\"diagnostic image 1\">",
"      Carotid stenosis by CDUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/15/9470\" title=\"diagnostic image 2\">",
"      Carotid artery stenosis by MRA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1118|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/36/11842\" title=\"figure 1\">",
"      Carotid stenosis in NASCET and ECST",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/27/40378?source=related_link\">",
"      Carotid endarterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/33/16922?source=related_link\">",
"      Management of asymptomatic carotid atherosclerotic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21530?source=related_link\">",
"      Management of symptomatic carotid atherosclerotic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/24/9608?source=related_link\">",
"      Pathophysiology of symptoms from carotid atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/14/12512?source=related_link\">",
"      Patient information: Carotid artery disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?29/34/30242?source=related_link\">",
"      Patient information: Doppler ultrasound (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/55/24435?source=related_link\">",
"      Patient information: Stroke (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/37/38484?source=related_link\">",
"      Patient information: Stroke symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/35/5689?source=related_link\">",
"      Principles of magnetic resonance imaging",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_19_31034="Approach to the diagnosis and treatment of wide QRS complex tachycardias";
var content_f30_19_31034=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/19/31034/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/19/31034/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/19/31034/contributors\">",
"     Leonard I Ganz, MD, FHRS, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/19/31034/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/19/31034/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/19/31034/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/19/31034/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/19/31034/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/19/31034/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/19/31034/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 4, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tachycardias are broadly categorized based upon the width of the QRS complex on the electrocardiogram (ECG).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A narrow QRS complex (&lt;120 msec) reflects rapid activation of the ventricles via the normal His-Purkinje system, which in turn suggests that the arrhythmia originates above or within the atrioventricular (AV) node (ie, a supraventricular tachycardia).",
"     </li>",
"     <li>",
"      A widened QRS (&ge;120 msec) occurs when ventricular activation is abnormally slow, most commonly because the arrhythmia originates outside of the normal conduction system (eg, ventricular tachycardia), or because of abnormalities within the His-Purkinje system (eg, supraventricular tachycardia with aberrancy). Much less common are pre-excited tachycardias; these are supraventricular tachycardias with antegrade conduction over an accessory pathway into the ventricular. This only occurs in a minority of patients with pre-excitations syndromes (Wolff-Parkinson-White Syndrome).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A wide complex tachycardia (WCT) represents a unique clinical challenge for two reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnosing the arrhythmia is difficult &mdash; Although most WCTs are due to ventricular tachycardia (VT), the differential diagnosis includes a variety of supraventricular tachycardias (SVTs). Diagnostic algorithms are complex and imperfect.",
"     </li>",
"     <li>",
"      Urgent therapy is often required &mdash; Patients may be unstable at the onset of the arrhythmia or deteriorate rapidly at any time. Therapeutic decisions are further complicated by the risks associated with giving therapy for an SVT to a patient who actually has VT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/1-4\">",
"       1-4",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Pharmacologic interventions'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H44\">",
"       'Uncertain diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Diagnostic uncertainty",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no single criterion or combination of criteria that provides complete diagnostic accuracy in evaluating a WCT. Algorithms that perform well in initial reports, with selected populations and experienced ECG analysts, are likely to be less accurate in general practice. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Algorithm performance'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Because the diagnosis of a WCT cannot always be made with complete certainty, an unknown rhythm should be presumed to be VT in the absence of contrary evidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/5\">",
"     5",
"    </a>",
"    ]. This conclusion is appropriate for several reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VT accounts for up to 80 percent of cases of WCT in unselected populations, and more than 90 percent of cases in patients with a prior myocardial infarction (MI) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/2,4,6,7\">",
"       2,4,6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Making the presumption of VT guards against inappropriate and potentially dangerous therapies directed at an SVT (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"       adenosine",
"      </a>",
"      , calcium channel blockers, or beta blockers), which can precipitate cardiac arrest in patients with VT. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Pharmacologic interventions'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Treatment of SVT as if it were VT (eg, with IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      , or external countershock) is safe and frequently effective in restoring sinus rhythm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of hemodynamic stability should",
"    <strong>",
"     not",
"    </strong>",
"    be regarded as diagnostic of SVT. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Stable patient'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The approach to and diagnosis of a wide QRS complex tachycardia will be reviewed here, with emphasis on the distinction between VT and SVT and the implications of this distinction on urgent management. The approach to a narrow QRS complex tachycardia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39481?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CAUSES OF WCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, a wide complex tachycardia (WCT) can be due to either VT or an SVT (",
"    <a class=\"graphic graphic_table graphicRef51512 \" href=\"mobipreview.htm?28/42/29355\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;VTs usually originate within the ventricular myocardium, outside of the normal conduction system. Compared to a normally conducted supraventricular beat, ventricular activation during VT is slower and proceeds in a different sequence. Thus, the QRS complex is wide and abnormal (",
"    <a class=\"graphic graphic_waveform graphicRef81690 \" href=\"mobipreview.htm?9/6/9318\">",
"     waveform 1",
"    </a>",
"    ). As there may be slight changes of the activation sequence during the VT, reflecting the abnormal pathway of impulse conduction, there may be subtle changes in QRS complex morphology of in the ST-T waves.",
"   </p>",
"   <p>",
"    VT is the most common cause of WCTs, particularly in patients with a history of cardiac disease. In series of unselected patients, VT accounted for up to 80 percent of cases of WCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/2,4,6,8\">",
"     2,4,6,8",
"    </a>",
"    ]. VT frequency can exceed 90 percent in patients with structural heart disease (eg, a prior MI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VT may be either monomorphic (having a uniform and a fairly stable QRS morphology during an episode) or polymorphic (having a continuously varying QRS complex morphology",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    axis during an episode). The features of each form of VT are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/8/43144?source=see_link\">",
"     \"Sustained monomorphic ventricular tachycardia: Diagnosis and evaluation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37641?source=see_link\">",
"     \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2202?source=see_link\">",
"     \"Clinical features of congenital long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Supraventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;When an SVT conducts to the ventricles via the normal atrioventricular (AV) node and His-Purkinje system, the activation wavefront spreads quickly through the ventricles and the QRS is usually narrow. However, any SVT (eg, atrial tachycardia, atrial fibrillation, atrial flutter, or an atrioventricular nodal reentrant tachycardia) can also produce a widened QRS by a number of mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aberrant conduction &mdash; The conduction of a supraventricular impulse can be delayed or blocked in the bundle branches or in the distal Purkinje system, resulting in a wide, abnormal QRS. This phenomenon is referred to as aberrancy. Aberrant conduction is the most common reason for a widened QRS during an SVT, but an aberrantly conducted SVT is still much less common than VT (eg, 21 percent of cases in one series) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18308?source=see_link\">",
"       \"Basic approach to delayed intraventricular conduction\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In some cases, the baseline ECG during sinus rhythm will have a left bundle branch block (LBBB), right bundle branch block (RBBB), or a nonspecific intraventricular conduction delay (IVCD). In such patients any SVT will have a widened QRS. Thus, if time allows, review of a baseline ECG can be helpful in differentiating VT from SVT with aberrancy. The presence of a conduction abnormality on the baseline ECG does not prove that the tachycardia is SVT with aberrancy, but the more similar the QRS during the WCT is to the QRS during sinus rhythm, the more likely it is that the WCT is an SVT with aberrancy.",
"      <br/>",
"      <br/>",
"      Alternatively, conduction may be normal during sinus rhythm but aberrant during the tachycardia. There are several reasons why this might occur. The most common is rate-related aberration (functional bundle branch block), in which rapidly generated impulses reach the conducting fibers before they have fully recovered from the previous impulse. Such a delay in recovery may be the result of underlying disease of the His-Purkinje system, hyperkalemia, or the actions of antiarrhythmic drugs, particularly the class IC agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/30/30182?source=see_link\">",
"       flecainide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26423?source=see_link\">",
"       propafenone",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=see_link\">",
"       \"Myocardial action potential and action of antiarrhythmic drugs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Preexcitation syndrome &mdash; In the preexcitation syndromes, AV conduction can occur over the normal conduction system and also via an accessory AV pathway (",
"      <a class=\"graphic graphic_figure graphicRef73740 graphicRef53773 graphicRef62454 \" href=\"mobipreview.htm?38/52/39752\">",
"       figure 1A-C",
"      </a>",
"      ). These two pathways create the anatomic substrate for a reentrant circuit, facilitating the development of a circus movement or reentrant tachycardia known as AV reentrant tachycardia (AVRT). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/43/21171?source=see_link\">",
"       \"ECG tutorial: Preexcitation syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24311?source=see_link&amp;anchor=H3#H3\">",
"       \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\", section on 'Orthodromic AVRT'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24311?source=see_link&amp;anchor=H4#H4\">",
"       \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\", section on 'Antidromic AVRT'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      AVRT can present with a narrow or a wide QRS complex:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If antegrade conduction to the ventricles occurs over the AV node and retrograde conduction back to the atria is over the accessory pathway, the QRS complex will be narrow (unless there is aberrant conduction, as discussed above). This narrow complex AVRT is known as an",
"      <strong>",
"       orthodromic",
"      </strong>",
"      AVRT (",
"      <a class=\"graphic graphic_figure graphicRef71302 \" href=\"mobipreview.htm?15/35/15926\">",
"       figure 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef68804 \" href=\"mobipreview.htm?6/4/6217\">",
"       waveform 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If antegrade conduction occurs over an accessory pathway and retrograde conduction occurs over the AV node or a second accessory pathway, the QRS complex will be wide. This is known as an",
"      <strong>",
"       antidromic",
"      </strong>",
"      AVRT (",
"      <a class=\"graphic graphic_figure graphicRef50433 \" href=\"mobipreview.htm?34/52/35655\">",
"       figure 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_waveform graphicRef54484 \" href=\"mobipreview.htm?24/55/25464\">",
"       figure 4",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Antidromic AVRT is a relatively uncommon cause of WCT (6 percent of cases in one series) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/8\">",
"       8",
"      </a>",
"      ]. It is difficult to differentiate from VT, because ventricular activation starts outside the normal intraventricular conduction system in both types of tachycardia. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'VT versus AVRT'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, patients with an accessory pathway may develop a different SVT (eg, atrial tachycardia, atrial fibrillation, or atrial flutter). In such cases, the QRS could be either narrow or wide, depending upon whether ventricular activation occurs over the normal conduction system, the accessory pathway, or both (",
"    <a class=\"graphic graphic_waveform graphicRef60790 \" href=\"mobipreview.htm?41/16/42250\">",
"     waveform 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef75523 \" href=\"mobipreview.htm?42/59/43962\">",
"     waveform 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_waveform graphicRef71133 \" href=\"mobipreview.htm?36/31/37370\">",
"     waveform 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pacemakers and defibrillators &mdash; When the ventricles are activated by a pacing device, the QRS complex is generally wide:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Most ventricular pacemakers pace the right ventricular apex, causing a wide QRS complex of the LBBB type. Most importantly, there is a broad R wave in lead I, which is an R to L bipolar lead. Impulses directed toward the left produce a positive deflection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31510?source=see_link\">",
"       \"Overview of cardiac pacing in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pacemakers used in cardiac resynchronization therapy (CRT) usually pace both ventricles. Although CRT generates a QRS complex that is narrower than the patient's baseline (a chronically widened QRS is one of the components of the indication for CRT), it is still usually longer than 120 msec. The important finding indicating CRT is the presence of a Q wave or QS complex in lead I, indicating activation going from left to right. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=see_link\">",
"       \"Cardiac resynchronization therapy in heart failure: Indications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most contemporary ICDs also have pacemaker (or CRT) capabilities; pacing will create a wide QRS complex similar to those devices. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=see_link\">",
"       \"General principles of the implantable cardioverter-defibrillator\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Recognizing that a QRS complex is due to ventricular pacing can be challenging, particularly during a tachycardia. In addition to characteristic QRS morphology, a pacing \"spike\" or stimulus artifact can often be identified. The stimulus artifact is a narrow electrical signal too rapid to represent myocardial depolarization. With unipolar pacemakers (more common in older devices), the spike is large and easily seen. However, bipolar pacemakers produce a smaller stimulus artifact, which is often difficult to detect on the surface ECG. Thus, the presence of the pacemaker, if not known from the patient's history and physical examination, may not always be identifiable by examination of the ECG alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients with a pacemaker or an ICD, further possibilities need to be considered in addition to the usual differential diagnosis of a WCT. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the presence of sinus tachycardia or some SVTs (eg, an atrial tachycardia, atrial flutter, or atrial fibrillation), the device may \"track\" the atrial impulse and pace the ventricle at the rapid rate, resulting in a WCT. However, two features of device programming reduce the likelihood of this occurring. First, most devices are programmed to \"track\" atrial activity only up to a certain heart rate (usually 120 to 130 beats per minute). At faster atrial rates, the ventricle will usually be paced at the upper programmed limit, but below the atrial rate, and AV dissociation may be detected. Second, most pacemakers recognize very fast atrial rates as abnormal, and will automatically switch to a mode that does not track such rates. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1849?source=see_link&amp;anchor=H10#H10\">",
"       \"Modes of cardiac pacing: Nomenclature and selection\", section on 'Mode switching'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A WCT can result if ventricular paced beats are conducted retrograde (backward) through the AV node to the atrium, resulting in an atrial signal, which the pacemaker senses and tracks with another ventricular stimulus. This ventricular paced beat is also conducted retrograde, and the cycle repeats indefinitely, a process termed pacemaker mediated tachycardia or endless loop tachycardia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These and other arrhythmias associated with pacemakers are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38295?source=see_link&amp;anchor=H7#H7\">",
"     \"Unexpected rhythms with normally functioning Dual-Chamber Pacing Systems\", section on 'Pacemaker-mediated tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Artifact mimicking VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECG artifact, particularly when observed on a rhythm strip, may be misdiagnosed as VT and can result in unnecessary invasive procedures (",
"    <a class=\"graphic graphic_waveform graphicRef62575 \" href=\"mobipreview.htm?41/24/42374\">",
"     waveform 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/9\">",
"     9",
"    </a>",
"    ]. The presence of narrow-complex beats that can be seen to \"march\" through the supposed WCT at a fixed rate strongly supports the diagnosis of artifact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first priority when evaluating a patient with a WCT is an assessment of patient stability. Unstable patients should be treated immediately, before an extensive diagnostic evaluation.",
"   </p>",
"   <p>",
"    In a stable patient, a focused clinical evaluation should include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History",
"     </li>",
"     <li>",
"      Physical examination",
"     </li>",
"     <li>",
"      Laboratory testing",
"     </li>",
"     <li>",
"      Diagnostic maneuvers in selected patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The primary goals of the initial evaluation are to determine the etiology of the WCT and to elucidate any underlying conditions related to the event (eg, heart failure, myocardial ischemia, drug reaction, or electrolyte abnormalities).",
"   </p>",
"   <p>",
"    Evaluation of the electrocardiogram in this setting is uniquely complex and is presented as a separate section. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Evaluation of the electrocardiogram'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Assessment of stability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate assessments of the patient's vital signs and the level of consciousness are of primary importance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/6\">",
"     6",
"    </a>",
"    ]. In the discussions that follow, patients are categorized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stable &mdash; This refers to a patient showing no evidence of hemodynamic compromise despite a sustained rapid heart rate. Such patients should have continuous monitoring and frequent reevaluations due to the potential for rapid deterioration.",
"      <br/>",
"      <br/>",
"      The presence of hemodynamic stability should",
"      <strong>",
"       not",
"      </strong>",
"      be regarded as diagnostic of SVT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/4,10\">",
"       4,10",
"      </a>",
"      ]. Misdiagnosis of VT as SVT based upon hemodynamic stability is a common error that can lead to inappropriate and potentially dangerous therapy. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Pharmacologic interventions'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H44\">",
"       'Uncertain diagnosis'",
"      </a>",
"      below.)&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Unstable &mdash; This term refers to a patient with evidence of hemodynamic compromise, but who remains awake with a discernible pulse. In this setting, emergent synchronized cardioversion is the treatment of choice regardless of the mechanism of the arrhythmia. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Unstable patient'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Findings consistent with hemodynamic instability requiring urgent cardioversion include hypotension, angina, altered level of consciousness, and heart failure.",
"     </li>",
"     <li>",
"      Patients who become unresponsive or pulseless are considered to have a cardiac arrest and are treated according to standard resuscitation algorithms. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link\">",
"       \"Advanced cardiac life support (ACLS) in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/25/36248?source=see_link\">",
"       \"Basic life support (BLS) in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;When evaluating the stable patient with a WCT, the following historical features may be help to determine the likely etiology",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    guide therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of heart disease &mdash; The presence of structural heart disease, especially coronary heart disease and a previous MI, strongly suggests VT as an etiology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/4,7\">",
"       4,7",
"      </a>",
"      ]. In one report, over 90 percent of patients with a WCT and a previous MI had VT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/7\">",
"       7",
"      </a>",
"      ]. It is also important to establish whether a cardiac arrhythmia has occurred in the past and, if so, whether the patient is aware of the etiology.",
"     </li>",
"     <li>",
"      Presence of a pacemaker or ICD &mdash; The patient should be asked about the presence of pacemaker or ICD. Patients are instructed to carry identification cards providing information about such devices, which can facilitate device interrogation. The presence of either a pacemaker or an ICD raises the possibility of a device-associated WCT. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Supraventricular tachycardia'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      More importantly, the presence of an ICD implies that the patient is known to have an increased risk of ventricular tachyarrhythmias and suggests strongly (but does not prove) that the patient's WCT is VT. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=see_link\">",
"       \"General principles of the implantable cardioverter-defibrillator\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptoms &mdash; Symptoms are",
"      <strong>",
"       not",
"      </strong>",
"      useful in determining the diagnosis, but they are important as an indicator of the severity of hemodynamic compromise. Symptoms are primarily due to the elevated heart rate, associated heart disease, and the presence of left ventricular dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/4,6,7\">",
"       4,6,7",
"      </a>",
"      ]. Some patients with a WCT have few or no symptoms (palpitations, lightheadedness, diaphoresis), while others have severe manifestations including chest pain or angina, syncope, shock, seizures, and cardiac arrest [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Age &mdash; A WCT in a patient over the age of 35 years is likely to be VT (positive predictive value 85 percent in one series) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/11\">",
"       11",
"      </a>",
"      ]. SVT is more likely in younger patients (positive predictive value 70 percent). However, VT must be considered in younger patients, particularly those with a family history of ventricular arrhythmias or premature sudden cardiac death.",
"     </li>",
"     <li>",
"      Duration of the tachycardia &mdash; SVT is more likely if the tachycardia has recurred over a period of more than three years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/6\">",
"       6",
"      </a>",
"      ]. The first occurrence of the tachycardia after an MI strongly implies VT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many medications have proarrhythmic effects, and obtaining a medication history is among the first priorities in the evaluation of a patient with a WCT.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      QT prolonging drugs &mdash; The most common drug-induced WCT is a form of polymorphic VT called torsades de pointes (TdP). This arrhythmia is associated with QT interval prolongation when the patient is in sinus rhythm. Frequently implicated agents include antiarrhythmic drugs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      and certain antimicrobial drugs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      and the quinolones. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link&amp;anchor=H4#H4\">",
"       \"Acquired long QT syndrome\", section on 'Drug-induced TdP'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      An internet resource with updated lists of specific drugs that cause TdP is available at the University of Arizona Center for Education and Research on Therapeutics website (",
"      <a class=\"external\" href=\"file://www.torsades.org/\">",
"       www.torsades.org",
"      </a>",
"      or",
"      <a class=\"external\" href=\"file://www.qtdrugs.org/\">",
"       www.qtdrugs.org",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Class I antiarrhythmic drugs &mdash; The class I antiarrhythmic drugs can cause both aberrancy during an SVT and also VT. These drugs, especially class IC agents, slow conduction and have a property of \"use-dependency\" (a progressive decrease in impulse conduction velocity at faster heart rates). As a result, these drugs can cause rate-related aberration and a wide QRS complex during any SVT. However, they can also cause VT with a very wide, bizarre QRS, which may be incessant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Supraventricular tachycardia'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=see_link\">",
"       \"Myocardial action potential and action of antiarrhythmic drugs\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      &mdash; Digoxin can cause almost any cardiac arrhythmia, especially at plasma concentrations above 2.0",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      (2.6",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      Digoxin-induced arrhythmias are more frequent at any given plasma concentration if hypokalemia is also present. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28072?source=see_link\">",
"       \"Basic approach to arrhythmias due to digoxin toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diuretics &mdash; Diuretics are a common cause of hypokalemia and hypomagnesemia, which may predispose to ventricular tachyarrhythmias, particularly TdP. The risk of TdP in the presence of hypokalemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypomagnesemia is greatest in patients taking antiarrhythmic drugs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=see_link&amp;anchor=H14#H14\">",
"       \"Acquired long QT syndrome\", section on 'Hypokalemia, hypomagnesemia, and hypocalcemia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with the history, the initial physical examination should focus upon evidence of underlying cardiovascular disease which can impact the likelihood that the WCT is VT.",
"   </p>",
"   <p>",
"    Findings suggestive of cardiovascular disease include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs of acute or chronic heart failure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41079?source=see_link\">",
"       \"Treatment of acute decompensated heart failure: General considerations\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=see_link\">",
"       \"Evaluation of the patient with suspected heart failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A healed sternal incision as evidence of previous cardiothoracic surgery.",
"     </li>",
"     <li>",
"      The sequelae of peripheral artery disease or stroke.",
"     </li>",
"     <li>",
"      A pacemaker or ICD. These devices are usually palpable and are in the left or, less commonly, right pectoral area below the clavicle; some earlier ICDs are found in the anterior abdominal wall.",
"      <br/>",
"      <br/>",
"      For those familiar with these devices, an ICD can be distinguished from a pacemaker by its size and shape, and, on x-ray, by the presence of defibrillator coils on the lead. An overpenetrated radiograph that shows the generator may permit specific device identification, because a radiopaque identifier is incorporated by the manufacturer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the physical examination can reveal evidence of AV dissociation, which is present in up to 75 percent of patients with VT, although it is not always easy to detect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/6,7,15\">",
"     6,7,15",
"    </a>",
"    ]. During AV dissociation, the normal coordination of atrial and ventricular contraction is lost, which may produce characteristic physical findings. The presence of AV dissociation strongly suggests VT, although its absence is less helpful.",
"   </p>",
"   <p>",
"    Although AV dissociation is typically diagnosed on the ECG (see",
"    <a class=\"local\" href=\"#H19\">",
"     'AV dissociation'",
"    </a>",
"    below), characteristic physical examination findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Marked fluctuations in the blood pressure because of the variability in the degree of left atrial contribution to LV filling, stroke volume, and cardiac output.",
"     </li>",
"     <li>",
"      Variability in the occurrence and intensity of heart sounds (especially S1) (\"cacophony of heart sounds\"), which is heard more frequently when the rate of the tachycardia is slower. Cannon \"A\" waves upon examination of the jugular pulsation in the neck. Cannon waves are intermittent and irregular jugular venous pulsations of greater amplitude than normal waves. They reflect simultaneous atrial and ventricular activation, resulting in contraction of the right atrium against a closed tricuspid valve. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33719?source=see_link\">",
"       \"Examination of the jugular venous pulse\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Prominent A waves can also be seen during some SVTs. Such prominent waves result from simultaneous atrial and ventricular contraction occurring with every beat.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Maneuvers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response of the arrhythmia to maneuvers may provide insight to the mechanism of the WCT. However, these interventions also carry some risk and should only be performed by experienced individuals in an environment capable of dealing with potential sequelae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Carotid sinus pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid sinus pressure enhances vagal tone and therefore depresses sinus and AV nodal activity. Examples of how various arrhythmias respond to carotid pressure include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sinus tachycardia will gradually slow with carotid sinus pressure and then accelerate upon release.",
"     </li>",
"     <li>",
"      During atrial tachycardia or atrial flutter, the ventricular response will transiently slow (due to increased AV nodal blockade). The arrhythmia itself, which occurs within the atria, is unaffected.",
"     </li>",
"     <li>",
"      A paroxysmal SVT (either AVNRT or AVRT) frequently terminates with carotid sinus pressure.",
"     </li>",
"     <li>",
"      VT is generally unaffected by vagal maneuvers such as carotid sinus pressure or valsalva, although these maneuvers may slow or block retrograde conduction. In some cases, this response exposes AV dissociation by altering the sinus rate (or PP intervals). Rarely, VT terminates in response to carotid sinus pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Pharmacologic interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of certain drugs can provide diagnostic information. However, some drugs used for the diagnosis or treatment of SVT (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"     adenosine",
"    </a>",
"    , or beta blockers) can cause severe hemodynamic deterioration (often the result of hypotension) in patients with a VT that is initially hemodynamically tolerated and can provoke ventricular fibrillation (VF) and cardiac arrest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Thus, these medications are generally reserved for the treatment of patients in whom the diagnosis of SVT is already known; they are rarely used for diagnostic purposes for a WCT.",
"   </p>",
"   <p>",
"    The diagnostic implications of the responses to certain medications include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Termination of the arrhythmia with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      suggests, but does not prove, that VT is the mechanism. Infrequently an SVT, especially AVRT, terminates with lidocaine.",
"     </li>",
"     <li>",
"      Termination of the arrhythmia with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"       adenosine",
"      </a>",
"      strongly implies SVT. However, VT can rarely terminate after the administration of these drugs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26858?source=see_link&amp;anchor=H22#H22\">",
"       \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\", section on 'Idiopathic left ventricular tachycardia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Termination of the arrhythmia with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      does not distinguish between VT and SVT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Additional tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of additional tests may provide further insight to the mechanism of the tachycardia and the presence of associated conditions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laboratory tests &mdash; The plasma potassium and magnesium concentrations should be measured as part of the initial evaluation, since hypokalemia and hypomagnesemia both predispose to the development of ventricular tachyarrhythmias. Hyperkalemia can cause a wide QRS complex rhythm with the loss of a detectable P wave, although this usually has a slow rate (so-called \"sinoventricular rhythm\"). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/5/33882?source=see_link\">",
"       \"Causes and evaluation of hyperkalemia in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35558?source=see_link&amp;anchor=H11#H11\">",
"       \"ECG tutorial: Miscellaneous diagnoses\", section on 'Hyperkalemia'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In patients taking",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"       procainamide",
"      </a>",
"      , plasma concentrations of these drugs should be measured to assist in evaluating possible toxicity.",
"     </li>",
"     <li>",
"      Chest x-ray &mdash; A chest x-ray can provide evidence suggestive of structural heart disease, such as cardiomegaly. Evidence of previous cardiothoracic surgery and the presence of a pacemaker or ICD can also be detected.",
"     </li>",
"     <li>",
"      Electrophysiologic study &mdash; Electrophysiologic testing allows definitive diagnosis of a WCT, but is rarely feasible in the acute setting. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/1/3097?source=see_link\">",
"       \"Invasive cardiac electrophysiology studies: Tachyarrhythmias\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     EVALUATION OF THE ELECTROCARDIOGRAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The electrocardiogram (ECG) can provide a probable diagnosis for a WCT in many patients. However, definitive diagnosis is not always possible and may be time-consuming, especially for clinicians unfamiliar with the criteria for distinguishing VT from SVT.",
"   </p>",
"   <p>",
"    In the hemodynamically stable patient, the ECG should be carefully examined. It should be compared to a previous ECG, if available. However, if there are any questions regarding the patient's stability, detailed ECG evaluation should be deferred in favor of urgent therapy. If time allows, an ECG should be obtained for later review. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Unstable patient'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following discussion outlines the features on the ECG that suggest VT or SVT. To perform an adequate ECG analysis, both a 12-lead ECG and a rhythm strip should be obtained. If available, a previous ECG when the patient was in normal sinus rhythm may be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Basic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard initial approach includes an assessment of rate, regularity, axis, and QRS duration.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rate &mdash; The rate of the WCT is of limited use in distinguishing VT from SVT. When the rate is approximately 150 beats per minute, atrial flutter with aberrant conduction should be considered, although this diagnosis should not be accepted without other supporting evidence.",
"     </li>",
"     <li>",
"      Regularity &mdash; VT is generally regular, although slight variation in the RR intervals is sometimes seen. Slight irregularity suggests VT as opposed to most SVTs, which are characterized by uniformity of the RR intervals. When the onset of the arrhythmia is available for analysis, a period of irregularity (\"warm-up phenomenon\"), suggests VT. More marked irregularity of RR intervals occurs in polymorphic VT and in atrial fibrillation (AF) with aberrant conduction.",
"     </li>",
"     <li>",
"      Axis &mdash; The QRS axis in the frontal plane can be useful in distinguishing SVT from VT. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/262?source=see_link&amp;anchor=H13#H13\">",
"       \"Basic principles of electrocardiographic interpretation\", section on 'QRS axis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A right superior axis (axis from -90 to &plusmn;180&ordm;), sometimes called an indeterminate or &ldquo;northwest\" axis, is rare in SVT and strongly suggests VT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/6\">",
"       6",
"      </a>",
"      ]. One exception to this rule is an antidromic AVRT seen with the Wolff-Parkinson-White (WPW) syndrome (ventricular preexcitation). In this situation there is direct activation of the ventricular myocardium, bypassing the normal His-Purkinje system, and the QRS complex may have an indeterminate axis.",
"     </li>",
"     <li>",
"      Compared to the axis during sinus rhythm, an axis shift during the WCT of more than 40&ordm; suggests VT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a patient with a RBBB-like WCT, a QRS axis to the left of -30&ordm; suggests VT. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'QRS morphology'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In a patient with an LBBB-like WCT, a QRS axis to the right of +90&ordm; suggests VT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'QRS morphology'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      QRS duration &mdash; In general, a wider QRS favors VT. In a RBBB-like WCT, a QRS duration &gt;140 msec suggests VT; while in a LBBB-like WCT, a QRS duration &gt;160 msec suggests VT (see",
"      <a class=\"local\" href=\"#H23\">",
"       'QRS morphology'",
"      </a>",
"      below)&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/6,17\">",
"       6,17",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In an analysis of several studies, a QRS duration &gt;160 msec was a strong predictor of VT (likelihood ratio &gt;20:1) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/18\">",
"       18",
"      </a>",
"      ]. However, a QRS duration &gt;160 msec is not helpful in some settings, including SVT with an AV accessory pathway (see",
"      <a class=\"local\" href=\"#H29\">",
"       'VT versus AVRT'",
"      </a>",
"      below), the presence of drugs capable of slowing intraventricular conduction, such as class I antiarrhythmic drugs, and in association with hyperkalemia (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Medications'",
"      </a>",
"      above)&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/17,19,20\">",
"       17,19,20",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A QRS duration &lt;140 msec does not exclude VT, since VT originating from the septum or within the His-Purkinje system (as opposed to the myocardium) may be associated with a relatively narrow QRS complex. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26858?source=see_link&amp;anchor=H22#H22\">",
"       \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\", section on 'Idiopathic left ventricular tachycardia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Concordance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concordance is present when the QRS complexes in all six precordial leads (V1 through V6) are monophasic with the same polarity. They can either all be entirely positive with tall, monophasic R waves, or all be entirely negative with deep monophasic QS complexes. If any of the six leads has a biphasic QRS (qR or RS complexes), concordance is not present.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Negative concordance is strongly suggestive of VT but is not definitive. Rarely, SVT with LBBB aberrancy will demonstrate negative concordance, but there is almost always some evidence of an R wave in the lateral leads.",
"     </li>",
"     <li>",
"      Positive concordance is most often due to VT but can also occur in the relatively rare case of antidromic AVRT with a left posterior accessory pathway [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/6,17\">",
"       6,17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39256?source=see_link\">",
"       \"Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While the presence of concordance strongly suggests VT (&gt;90 percent specificity), its absence is not helpful diagnostically (approximately 20 percent sensitivity) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     AV dissociation",
"    </span>",
"    &nbsp;&mdash;&nbsp;AV dissociation is characterized by atrial activity that is independent of ventricular activity (",
"    <a class=\"graphic graphic_waveform graphicRef52123 \" href=\"mobipreview.htm?5/61/6104\">",
"     waveform 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In a WCT with AV dissociation, an atrial rate slower than the ventricular rate strongly suggests VT. An atrial rate that is faster than the ventricular rate is seen with some SVTs, such as atrial flutter or an atrial tachycardia with 2:1 AV conduction. In these settings, however, there is a consistent relationship between the P waves and the QRS complexes, so there is not true AV dissociation.",
"   </p>",
"   <p>",
"    While the presence of AV dissociation largely establishes VT as the diagnosis, its absence is not as helpful for two reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AV dissociation may be present but not obvious on the ECG.",
"     </li>",
"     <li>",
"      In some cases of VT, the ventricular impulses conduct backwards through the AV node and capture the atrium (referred to as retrograde conduction), preventing AV dissociation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/21\">",
"       21",
"      </a>",
"      ]. If the ECG demonstrates 2:1 retrograde conduction (a P wave after every other QRS) VT is likely but not certain since AVNRT with aberrancy and 2:1 retrograde conduction can also be seen, but it is uncommon. Such a pattern does, however, rule out AVRT since with this arrhythmia there needs to be a 1:1 relationship between P wave and QRS complex.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following findings are helpful in establishing the presence of AV dissociation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Dissociated P waves",
"    </span>",
"    &nbsp;&mdash;&nbsp;P waves are said to be dissociated if they are not consistently coupled to the QRS complexes, as evidenced by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      PP and RR intervals are different",
"     </li>",
"     <li>",
"      PR intervals are variable",
"     </li>",
"     <li>",
"      There is no association between P and QRS complexes",
"     </li>",
"     <li>",
"      The presence of a P wave with one, but not all, QRS complexes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During a WCT, P waves are often difficult to identify. If P waves are not evident on the surface ECG, direct recordings of atrial activity (eg, with an esophageal lead or an intracardiac catheter) can reveal AV dissociation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Fusion beats",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusion occurs when one impulse originating from the ventricle and a second supraventricular impulse simultaneously activate the ventricular myocardium. The resulting QRS complex has a morphology intermediate between that of a sinus beat and a purely ventricular complex (",
"    <a class=\"graphic graphic_waveform graphicRef72600 \" href=\"mobipreview.htm?4/46/4840\">",
"     waveform 8",
"    </a>",
"    ). Intermittent fusion beats during a WCT are diagnostic of AV dissociation and therefore of VT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Capture beats",
"    </span>",
"    &nbsp;&mdash;&nbsp;Capture beats, or Dressler beats, are QRS complexes during a WCT that are identical to the sinus QRS complex (",
"    <a class=\"graphic graphic_waveform graphicRef72600 \" href=\"mobipreview.htm?4/46/4840\">",
"     waveform 8",
"    </a>",
"    ). The term \"capture beat\" implies that the normal conduction system has momentarily \"captured\" control of ventricular activation from the VT focus.",
"   </p>",
"   <p>",
"    Fusion beats and capture beats are more commonly seen when the tachycardia rate is slower.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     QRS morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frequently, the above criteria do not provide a definitive diagnosis. Further ECG evaluation involves assessment of the morphology of the QRS complex.",
"   </p>",
"   <p>",
"    Analysis of QRS morphology is based upon an understanding of the relationships between the sites of tachycardia origin, ventricular activation patterns, and the resulting morphologies of the QRS complex in the 12 standard ECG leads.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of criteria have been developed to facilitate the evaluation of QRS morphology. However, the value of these morphologic criteria is subject to several limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Associations between the QRS morphology and WCT diagnosis are often based upon statistical correlations with substantial overlap.",
"     </li>",
"     <li>",
"      Morphologic criteria favoring VT can be present in patients with an intraventricular conduction delay during sinus rhythm, limiting their applicability in these cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Morphologic criteria tend to misclassify antidromic AVRT as VT. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'VT versus AVRT'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the discussions that follow, upper-case and lower-case letters are used to indicate the relative magnitude of the described electrocardiographic waves. As examples, the term \"qR\" implies a small Q wave followed by a large R wave.",
"   </p>",
"   <p>",
"    Most of these approaches involve classifying the WCTs as having one of two patterns:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An RBBB-like pattern &mdash; QRS polarity is positive in leads V1 and V2",
"     </li>",
"     <li>",
"      An LBBB-like pattern &mdash; QRS polarity is negative in leads V1 and V2",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This distinction does not, by itself, make the diagnosis, but additional features favor VT in either RBBB-like or LBBB-like WCTs.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      V1 positive (RBBB) pattern &mdash; In the patient with a WCT and positive QRS polarity in lead V1, the following associations have been made [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/6,8,17,24-26\">",
"       6,8,17,24-26",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Findings in lead V1 &mdash; A monophasic R or biphasic qR complex in lead V1 favors VT.",
"      <br/>",
"      <br/>",
"      A triphasic RSR' or RsR' complex (the so-called \"rabbit-ear\" sign) in lead V1 usually favors SVT. As an exception, if the left peak of the RsR' complex is taller than the right peak, VT is more likely [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/18,27\">",
"       18,27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Findings in lead V6 &mdash; An rS complex (R wave smaller than S wave) in lead V6 favors VT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/18\">",
"       18",
"      </a>",
"      ]. In contrast, an Rs complex (R wave larger than S wave) in lead V6 favors SVT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      V1 negative (LBBB) pattern &mdash; In the patient with a WCT and negative QRS polarity in lead V1, the following associations have been made [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/6,8,17,24-26\">",
"       6,8,17,24-26",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Findings in lead V1 or V2 &mdash; A broad initial R wave of 40 msec duration or longer in lead V1 or V2 favors VT. In contrast, the absence of an initial R wave or a small initial R wave of less than 40 msec in lead V1 or V2 favors SVT.",
"      <br/>",
"      <br/>",
"      Two other findings that favor VT are a slurred or notched downstroke of the S wave in lead V1 or V2, and a duration from the onset of the QRS complex to the nadir of the QS or S wave of &ge;60 msec in lead V1 or V2. In contrast, a swift, smooth downstroke of the S wave in lead V1 or V2 with a duration of &lt;60 msec favors SVT.",
"      <br/>",
"      <br/>",
"      In an analysis of several studies, the presence of any of these three criteria (broad R wave, slurred or notched downstroke of S wave, and delayed nadir of S wave) was a strong predictor of VT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Findings in lead V6 &mdash; The presence of any Q or QS wave in lead V6 favors VT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/18\">",
"       18",
"      </a>",
"      ]. In contrast, the absence of a Q wave in lead V6 favors SVT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Variation in QRS and ST-T shape",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subtle, non-rate-related fluctuations or variations in QRS and ST-T wave configuration suggest VT and may reflect variations in the VT reentrant circuit within the myocardium as well as a subtle difference in the activation sequence of the myocardium reflecting activation that bypasses the normal conduction system. AV dissociation can cause variability in the ST segment and T wave morphology. In contrast, SVT, because it follows a fixed conduction pathway to and through the ventricular myocardium, is characterized by uniformity of QRS and ST-T shape unless the rate changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ALGORITHMS FOR WCT DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients will have some, but not all, of the features favoring VT. It is necessary, therefore, to integrate ECG findings into a diagnostic strategy. Several such a strategies, or algorithms, have been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/18,28,29\">",
"     18,28,29",
"    </a>",
"    ]. The Brugada are the most widely known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Brugada criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Brugada criteria are a stepwise approach in which four criteria for VT are sequentially assessed (",
"    <a class=\"graphic graphic_algorithm graphicRef73159 \" href=\"mobipreview.htm?24/3/24638\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/28\">",
"     28",
"    </a>",
"    ]. If any of the criteria is satisfied, the diagnosis of VT is made, and if none are fulfilled, an SVT is diagnosed. An exception is an antidromic AVRT in WPW syndrome.",
"   </p>",
"   <p>",
"    The steps are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leads V1-V6 are inspected to detect an RS complex. If there are no RS complexes, concordance is present and the diagnosis of VT can be made. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Concordance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If an RS complex is present, the interval between the onset of the R wave and the nadir of the S wave (RS interval) is measured. If the longest RS interval in any lead is &gt;100 msec and the R wave is wider than the S wave, the diagnosis of VT can be made. This reflects the fact that aberration is due to a terminal delay and a wider terminal portion of the QRS complex (ie, S wave), while with VT even the initial portion of the QRS complex (ie, R wave) is wide and abnormal.",
"     </li>",
"     <li>",
"      If the longest RS interval is &lt;100 msec, the presence or absence of AV dissociation is assessed. If AV dissociation is seen, the diagnosis of VT is made. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'AV dissociation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the RS interval is &lt;100 msec and AV dissociation cannot clearly be demonstrated, the QRS morphology criteria for V1-positive and V1-negative wide QRS complex tachycardias are considered. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'QRS morphology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    QRS morphology criteria consistent with VT must be present in leads V1 or V2 and in lead V6 to diagnose VT. If either the V1-V2 or the V6 criteria are not consistent with VT, an SVT is assumed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Alternative approaches",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An alternative algorithm uses a stepwise approach similar to the Brugada criteria, but includes different ECG features (",
"      <a class=\"graphic graphic_algorithm graphicRef79624 \" href=\"mobipreview.htm?19/12/19662\">",
"       algorithm 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/29\">",
"       29",
"      </a>",
"      ]. Two unique features of this algorithm include an initial R wave in aVR (diagnostic of VT), and the Vi:Vt ratio. Vi and Vt are the magnitude of voltage change in the initial and terminal 40 msec of a QRS, respectively. A Vi:Vt ratio &le;1 is diagnostic of VT.",
"     </li>",
"     <li>",
"      A Bayesian approach utilizes likelihood ratios (LR) for six ECG criteria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/18\">",
"       18",
"      </a>",
"      ]. Patients are presumed to start with a \"prior odds ratio\" of 4.0 (4:1) in favor of VT. As each criterion is evaluated sequentially, the associated LR is multiplied by the prior odds ratio to calculate the new probability of VT. The final odds ratio (posterior probability) is considered consistent with VT if the value is &ge;1.0, and SVT if the value is &lt;1.0.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     VT versus AVRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Differentiation between VT and an antidromic AVRT is particularly difficult. Because ventricular activation begins outside of the normal conduction system in both tachycardias, many of the standard criteria are not able to discriminate antidromic AVRT from VT. The clinical significance of this problem is often limited, however, because preexcitation is an uncommon cause of WCT (6 percent in one series) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/8\">",
"     8",
"    </a>",
"    ]. This is particularly true if other factors (eg, age, underlying heart disease) suggest VT.",
"   </p>",
"   <p>",
"    For cases in which preexcitation is thought to be likely (such as a young patient without structural heart disease, or a patient with a known accessory pathway), a separate algorithm was developed by the Brugada group. Their second algorithm consists of the following three steps (",
"    <a class=\"graphic graphic_algorithm graphicRef59336 \" href=\"mobipreview.htm?39/2/39982\">",
"     algorithm 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The predominant polarity of the QRS complex in leads V4 through V6 is defined either as positive or negative. If predominantly negative, the diagnosis of VT can be made.",
"     </li>",
"     <li>",
"      If the polarity of the QRS complex is predominantly positive in V4 through V6, the ECG should be examined for the presence of a qR complex in one or more of precordial leads V2 through V6. If a qR complex can be identified, VT can be diagnosed.",
"     </li>",
"     <li>",
"      If a qR wave in leads V2 through V6 is absent, the AV relationship is then evaluated (AV dissociation). If a 1:1 AV relationship is not present and there are more QRS complexes present than P waves, VT can be diagnosed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the ECG of the arrhythmia does not display any morphologic characteristics diagnostic of VT after using this algorithm, the diagnosis of antidromic AVRT must be considered. When any of these criteria are met, VT is likely. However, it is difficult to make the diagnosis of SVT with confidence, because up to 25 percent of WCTs that meet none of these criteria is actually VT. Importantly, the presence of AV dissociation eliminates AVRT as there must be 1:1 AV association for AVRT to exist. In addition, the QRS complex morphology and ST-T waves are uniform with AVRT as every impulse to the ventricle is conducted through the same accessory pathway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Algorithm performance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Algorithms often perform well in initial reports. However, such studies include selected populations and experienced ECG analysts.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In its initial description, the reported sensitivity and specificity of the Brugada criteria were 98.7 and 96.5 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/28\">",
"       28",
"      </a>",
"      ]. However, in two subsequent reports in which a total of nine clinicians (two cardiologists, two emergency department clinicians, and five internists) used these criteria in interpreting a total of 168 WCTs that had been diagnosed with electrophysiologic testing, the sensitivity ranged from 79 to 92 percent, and specificity from 43 to 70 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a comparison of the Brugada criteria and the Bayesian approach, the two approaches performed similarly, with sensitivities of 92 and 97 and specificities of 44 and 56 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the initial description of the alternative algorithm described above, it was significantly more accurate than the Brugada criteria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/29\">",
"       29",
"      </a>",
"      ]. Further study is necessary to confirm both the overall accuracy of this approach and its superiority to the Brugada criteria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation of a WCT is often superseded by the management of the arrhythmia, especially in the unstable patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Unstable patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodynamic compromise may occur with any WCT, regardless of the etiology. Furthermore, patients who initially appear stable may deteriorate rapidly.",
"   </p>",
"   <p>",
"    When a patient with a WCT is unstable, but still responsive with a discernible blood pressure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulse, we recommend the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Emergent synchronized cardioversion &mdash; Initial cardioversion is performed with a synchronized shock of 100 to 200 joules (monophasic) or 50 to 100 joules (biphasic), with titration of the energy upward as needed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11050?source=see_link&amp;anchor=H2562597#H2562597\">",
"       \"Cardioversion for specific arrhythmias\", section on 'Energy selection for defibrillation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the QRS complex and T wave cannot be distinguished accurately, a synchronized shock may not be possible. Such patients should be treated with immediate defibrillation (ie, unsynchronized shock using 360 joules [monophasic] or 200 joules [biphasic]).",
"     </li>",
"     <li>",
"      The cautious use of intravenous analgesics or sedatives may be appropriate. However, the use of such agents must be balanced against the risks of further hemodynamic deterioration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who become unresponsive or pulseless should be managed according to standard ACLS resuscitation algorithms, with immediate high-energy defibrillation and CPR (",
"    <a class=\"graphic graphic_algorithm graphicRef73862 \" href=\"mobipreview.htm?42/63/44022\">",
"     algorithm 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/25/36248?source=see_link\">",
"     \"Basic life support (BLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/24/8585?source=see_link\">",
"     \"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Stable patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a patient who is hemodynamically stable, additional time can be given to determining the diagnosis, and therapy may be targeted to the specific arrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Ventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In stable patients with VT or an uncertain diagnosis that is being managed with the presumed diagnosis of VT (see",
"    <a class=\"local\" href=\"#H44\">",
"     'Uncertain diagnosis'",
"    </a>",
"    below), the following approach is recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urgent or elective cardioversion is usually appropriate. Following appropriate conscious sedation, an initial synchronized shock of 100 to 200 joules (monophasic) or 50 to 100 joules (biphasic) is administered. Repeated shocks at higher energies may be performed as necessary.",
"     </li>",
"     <li>",
"      Class I and III antiarrhythmic drugs are generally reserved for refractory or recurrent arrhythmias. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Recurrent or refractory WCT'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Any associated conditions should be treated, including cardiac ischemia, heart failure, electrolyte abnormalities, or drug toxicities.",
"     </li>",
"     <li>",
"      For patients with one of the known syndromes of VT in structurally normal hearts, calcium channel blockers or beta blockers may be used, particularly if the patient has been successfully treated in the past with such medications. These drugs can be used either to terminate the arrhythmia, or after cardioversion to suppress recurrences. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26858?source=see_link\">",
"       \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, given the risk for hemodynamic deterioration following the administration of these medications, an external defibrillator should be immediately available prior to administration. Furthermore, the decision to use these medications in this setting, particularly if there is any uncertainty regarding the diagnosis, should be made in conjunction with a cardiologist who is experienced in arrhythmia management. If such expertise is not immediately available, electrical cardioversion is generally preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Supraventricular tachycardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;When there is no doubt that the WCT is an SVT, therapy directed at the SVT may be given. In such cases, management is similar to an SVT with a normal QRS duration.",
"   </p>",
"   <p>",
"    The ECG recording when the tachycardia slows or terminates can provide valuable information for diagnosing the specific type of SVT. Thus, in a stable patient, a continuous rhythm strip, preferably a 12-lead rhythm strip, should be recorded during any intervention intended to terminate the arrhythmia or slow the ventricular response.",
"   </p>",
"   <p>",
"    If the SVT is likely to be AVNRT or AVRT, or if the specific SVT diagnosis is uncertain, the following treatments are recommended:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vagotonic maneuvers &mdash; We recommend carotid sinus pressure (if no carotid bruits are present) or valsalva maneuver as the initial intervention.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"       Adenosine",
"      </a>",
"      &mdash; Adenosine (6 mg IV over 1-2 seconds) is highly effective in terminating many SVTs (eg, AVNRT, AVRT), and for others (eg, AF, atrial flutter), adenosine may facilitate the diagnosis by slowing the ventricular response to allow clearer assessment of atrial activity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/19/31034/abstract/6\">",
"       6",
"      </a>",
"      ]. If the initial dose is ineffective, a 12 mg dose may be given and repeated once if necessary.",
"      <br/>",
"      <br/>",
"      Adenosine has a very short half-life (less than 10 seconds), reducing the risk of an untoward reaction. However, adenosine can cause degeneration to VF, particularly in patients with coronary artery disease. Thus, an external defibrillator should be immediately available if adenosine is given.",
"     </li>",
"     <li>",
"      Calcium channel blockers or beta blockers &mdash; Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      (2.5 to 5 mg IV), or beta blockers (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      5 to 10 mg IV) may be given if the SVT persists after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"       adenosine",
"      </a>",
"      administration. These medications can terminate AVNRT or AVRT, as well as some atrial tachycardias. If the specific SVT diagnosis remains unknown, these drugs may slow the ventricular response and facilitate diagnosis.",
"     </li>",
"     <li>",
"      Cardioversion &mdash; Cardioversion is rarely necessary in patients with a stable SVT. However, if AVNRT or AVRT persist after the above interventions, synchronized cardioversion is usually effective in restoring sinus rhythm. Following appropriate conscious sedation, an initial synchronized shock of 100 to 200 joules (monophasic) or 50 to 100 joules (biphasic) is administered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the arrhythmia is known to be AF, atrial flutter, or an atrial tachycardia, management options include rate control and cardioversion (ie, rhythm control). Decisions regarding which strategy is appropriate in a given patient are addressed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/60/13256?source=see_link\">",
"     \"Overview of the evaluation and management of atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=see_link\">",
"     \"Overview of atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After the WCT is terminated or controlled, the further management of an SVT depends upon which SVT is present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24793?source=see_link\">",
"     \"Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Recurrent or refractory WCT",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the WCT recurs or persists following initial attempts at cardioversion, suppression of the arrhythmia by pharmacologic means should be attempted and further evaluation should focus upon the presence of arrhythmia triggers (eg, ischemia, electrolyte abnormalities, and drug toxicity). Cardioversion or defibrillation should be repeated as necessary in patients who are hemodynamically unstable.",
"   </p>",
"   <p>",
"    For patients with recurrent VT or a WCT of uncertain etiology, we recommend the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"      (150 mg IV over 10 minutes followed by an infusion of 1",
"      <span class=\"nowrap\">",
"       mg/minute",
"      </span>",
"      for 6 hours, then 0.5",
"      <span class=\"nowrap\">",
"       mg/minute)",
"      </span>",
"      is recommended in most settings, due to its efficacy in the suppression of both atrial and ventricular arrhythmias.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36391?source=see_link\">",
"       Procainamide",
"      </a>",
"      (15 to 18",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      administered as slow infusion over 25-30 minutes, followed by 1-4",
"      <span class=\"nowrap\">",
"       mg/minute",
"      </span>",
"      by continuous infusion) is an alternative to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      that also suppresses both SVTs and VT. In addition, because of its ability to suppress conduction over a bypass tract, procainamide is recommended if antidromic AVRT or an SVT conducting over a bypass tract is suspected. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15305?source=see_link\">",
"       \"Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      (1 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      over 2 to 3 minutes) may be useful, particularly if cardiac ischemia is suspected. In some cases lidocaine, may actually slow conduction in the accessory pathway and terminate an antidromic AVRT.",
"     </li>",
"     <li>",
"      In a patient with a stable blood pressure and recurrent arrhythmias, the cautious use of beta blockers (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      5 to 10 mg IV) may be initiated. Due to the possibility of precipitating hemodynamic deterioration, beta blockers should be administered in a setting where urgent defibrillation can be performed, if necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with a known SVT that recurs or persists, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    , or beta blockers may be used.",
"   </p>",
"   <p>",
"    Multiple recurrences of WCT should raise concern about cardiac ischemia, hypokalemia, digitalis toxicity, and polymorphic VT with or without QT prolongation, all of which have specific appropriate therapy. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1393749637\">",
"    <span class=\"h2\">",
"     Presence of a pacemaker",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the WCT is the result of the pacemaker tracking an underlying atrial arrhythmia or the result of a pacemaker mediated tachycardia, the appropriate therapy is the placement of a magnet over the pacemaker. The magnet will disable all pacemaker sensing and will thus terminate the ability of the pacemaker to track atrial impulses. With the magnet, the pacemaker will function in an asynchronous, fixed rate mode (ie, VOO or DOO). In this situation, there will be pacemaker stimuli that do not sense the P wave or QRS complex and will occur with a fixed rate (ie, the lower rate limit of the pacemaker). Although the ventricular stimuli will occasional occur on the T wave (similar to an R on T event), this does not usually result in any arrhythmia, as the output energy of the pacemaker is small and unlikely to provoke a ventricular tachyarrhythmia. However, if there is any evidence for ischemia, the output could potentially trigger a ventricular arrhythmia if there is an R on T phenomenon. In this situation, the pacemaker should be reprogrammed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38295?source=see_link&amp;anchor=H7#H7\">",
"     \"Unexpected rhythms with normally functioning Dual-Chamber Pacing Systems\", section on 'Pacemaker-mediated tachycardia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Presence of an ICD",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been a dramatic increase in use of ICDs for both the primary and secondary prevention of sudden cardiac death. The presence of an ICD has a number of unique implications for patients with a WCT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=see_link\">",
"     \"General principles of the implantable cardioverter-defibrillator\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although patients with an ICD should receive device therapies for a WCT, such therapies are usually delivered within the first minutes of the arrhythmia. In a patient with a persistent or recurrent WCT, the ICD should",
"    <strong>",
"     not",
"    </strong>",
"    be relied upon to provide definitive management.",
"   </p>",
"   <p>",
"    If an individual with expertise in device evaluation and management is available, the device should be interrogated. If the patient is stable, the device may be evaluated during the WCT.",
"   </p>",
"   <p>",
"    Device interrogation and programming can provide the following information and possible therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arrhythmia diagnosis, which is facilitated by both live and stored intracardiac recordings of the arrhythmia.",
"     </li>",
"     <li>",
"      The history of device therapies can be retrieved.",
"     </li>",
"     <li>",
"      The device can be manually triggered to deliver therapy.",
"     </li>",
"     <li>",
"      Therapies may be disabled to avoid inappropriate device discharges.",
"     </li>",
"     <li>",
"      The parameters determining device therapy may be adjusted to provide more appropriate therapies or to avoid inappropriate therapies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If an individual with expertise in ICD use is not immediately available, a general assessment can still be made. ICD behavior can be categorized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Effective ICD function (a single WCT episode is terminated by the ICD) &mdash; Some patients have a single tachycardia episode that is appropriately treated by the ICD, with no residual symptoms and immediate recovery of baseline clinical status. In such patients, a focused evaluation should seek evidence of arrhythmic triggers (eg, ischemia, decompensated HF, electrolyte abnormalities, or medication changes). In the absence of such triggers, an asymptomatic patient with a normally functioning ICD can often be discharged after device interrogation and a brief period of observation.",
"     </li>",
"     <li>",
"      Repeated ICD discharges, with successful arrhythmia termination followed by recurrence of the WCT &mdash; In this setting, evidence of arrhythmia triggers should be aggressively sought and suppression of the arrhythmia by pharmacologic means should be attempted, to prevent both arrhythmia recurrence and the debilitating physical experience of multiple device discharges. In contrast to patients with a single tachycardia event, patients with recurrent or refractory WCT events require close monitoring, usually in a critical care setting. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Recurrent or refractory WCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ICD discharge without arrhythmia termination &mdash; There are several possible explanations for this phenomenon. The ICD may be malfunctioning in a variety of ways. Alternatively, the defibrillation threshold (the amount of energy required to defibrillate the ventricle) may be higher than the therapies delivered by the device. Defibrillation thresholds are usually checked at the time of implantation, so this would usually reflect a threshold rise, which may be due to a new medication (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      ), or clinical deterioration. Finally, the arrhythmia may an SVT (usually AF) that does not convert with the device shocks, resulting in persistent tachycardia and repeated therapies. Regardless of the reason, this finding always requires close observation, evaluation of the device, and usually disabling of therapies until the issues are resolved.",
"     </li>",
"     <li>",
"      WCT without device discharge &mdash; There are several possible explanations for this occurrence: the device is not functioning appropriately; the WCT rate may be lower than the ICD's programmed rate for therapy; or the device diagnostics may define the rhythm as an SVT (a device is generally programmed to treat arrhythmias it defines as VT or VF). When no device therapies are being delivered and the device cannot be immediately interrogated (due either to lack of equipment or personnel, or patient instability), the initial management should proceed as if no ICD were present. The ICD should be evaluated once the patient has been stabilized. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Device discharge without WCT &mdash; This is always an indication of device malfunction, which must be addressed by reprogramming or disabling the ICD as soon as possible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Disabling an ICD",
"    </span>",
"    &nbsp;&mdash;&nbsp;In several of the setting described above, it may be necessary to reprogram or disable the ICD. If expertise in device programming is not available, a magnet should be applied over the device, which may inhibit device discharge. Cardiac monitoring must continue while the magnet is in place, because the patient is not protected from potentially life-threatening arrhythmias. The device should be fully evaluated to determine the cause of the malfunction before the patient is discharged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/51/27442?source=see_link\">",
"       \"Patient information: Ventricular tachycardia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following summary and recommendations apply to the initial evaluation and management of WCTs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Assessment of patient stability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate assessment of patient stability takes precedence over any further diagnostic evaluation. A patient who is unresponsive or pulseless should be treated according to standard ACLS algorithms (",
"    <a class=\"graphic graphic_algorithm graphicRef73862 \" href=\"mobipreview.htm?42/63/44022\">",
"     algorithm 4",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Assessment of stability'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a stable patient, a focused diagnostic evaluation may proceed to determine the etiology of the arrhythmia and guide specific therapy.",
"     </li>",
"     <li>",
"      In a patient who is unstable but conscious, we recommend immediate synchronized cardioversion (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Unstable patient'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a stable patient, a rapid diagnostic evaluation should focus upon features that help determine the likelihood of VT versus SVT, as well as associated medical conditions or potential arrhythmia triggers. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'General approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Definitive diagnosis, when possible, usually comes from the ECG. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Evaluation of the electrocardiogram'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Diagnosis of VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECG should be evaluated closely for the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Precordial lead concordance (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Concordance'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      AV dissociation (see",
"      <a class=\"local\" href=\"#H19\">",
"       'AV dissociation'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      QRS morphologic features (see",
"      <a class=\"local\" href=\"#H23\">",
"       'QRS morphology'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of any of these ECG features is adequate for the diagnosis of VT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Diagnosis of SVT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The absence of the historical or ECG features of VT does not confirm a diagnosis of SVT. Similarly, algorithms for the evaluation of WCTs are likely to be less accurate in general practice than in published reports. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Algorithm performance'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In the acute setting, the diagnosis of SVT should be reserved to the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a history of SVTs that have presented similarly.",
"     </li>",
"     <li>",
"      Young patients, whose hearts are structurally normal, in whom none of the historical (eg, family history of sudden cardiac death), physical, or ECG criteria supporting VT are present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Uncertain diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the diagnosis of a WCT is uncertain, we recommend that the patient be treated as if the rhythm is VT (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Diagnostic uncertainty'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H30\">",
"     'Algorithm performance'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In stable patients, initial therapy should be directed at the specific (or presumed) arrhythmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h3\">",
"     Ventricular tachycardias",
"    </span>",
"    &nbsp;&mdash;&nbsp;In stable patients with known or presumed VT, we recommend the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend synchronized external cardioversion, following appropriate conscious sedation, as the initial therapy for most patients with stable VT (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Ventricular tachycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with refractory or recurrent WCT, we suggest a class I or III antiarrhythmic drug (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Recurrent or refractory WCT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In selected patients known to have one of the syndromes of VT in the setting of a structurally normal heart, we suggest calcium channel blockers or beta blockers be used for arrhythmia termination or suppression (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, the decision to use these drugs in this setting should be made in consultation with a cardiologist experienced in arrhythmia management. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26858?source=see_link\">",
"       \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h3\">",
"     Supraventricular tachycardias",
"    </span>",
"    &nbsp;&mdash;&nbsp;In stable patients with a WCT that is known to be an SVT, initial management is similar to that of an SVT with a narrow QRS complex. A continuous rhythm strip should be obtained during any intervention that is intended to slow or terminate the arrhythmia.",
"   </p>",
"   <p>",
"    For AVNRT or AVRT, or an SVT in which the specific arrhythmia is unknown, we suggest the following sequence of interventions in order to terminate the arrhythmia or to slow ventricular response and facilitate diagnosis (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Supraventricular tachycardia'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vagotonic maneuvers (eg, valsalva or carotid sinus pressure)",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44454?source=see_link\">",
"       adenosine",
"      </a>",
"     </li>",
"     <li>",
"      Intravenous calcium channel blockers or beta blockers",
"     </li>",
"     <li>",
"      Cardioversion in selected persistent cases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For AF, atrial flutter, or atrial tachycardia, either rate or rhythm control may be appropriate. The selection of an initial management strategy for these arrhythmias is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/60/13256?source=see_link\">",
"     \"Overview of the evaluation and management of atrial flutter\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=see_link\">",
"     \"Overview of atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/1\">",
"      Buxton AE, Marchlinski FE, Doherty JU, et al. Hazards of intravenous verapamil for sustained ventricular tachycardia. Am J Cardiol 1987; 59:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/2\">",
"      Stewart RB, Bardy GH, Greene HL. Wide complex tachycardia: misdiagnosis and outcome after emergent therapy. Ann Intern Med 1986; 104:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/3\">",
"      Dancy M, Camm AJ, Ward D. Misdiagnosis of chronic recurrent ventricular tachycardia. Lancet 1985; 2:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/4\">",
"      Akhtar M, Shenasa M, Jazayeri M, et al. Wide QRS complex tachycardia. Reappraisal of a common clinical problem. Ann Intern Med 1988; 109:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/5\">",
"      European Heart Rhythm Association, Heart Rhythm Society, Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 2006; 48:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/6\">",
"      Gupta AK, Thakur RK. Wide QRS complex tachycardias. Med Clin North Am 2001; 85:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/7\">",
"      Tchou P, Young P, Mahmud R, et al. Useful clinical criteria for the diagnosis of ventricular tachycardia. Am J Med 1988; 84:53.",
"     </a>",
"    </li>",
"    <li>",
"     Miller JM, Hsia HH, Rothman SA, et al. Ventricular tachycardia versus supraventricular tachycardia with aberration: electrocardiographic distinctions. In: Cardiac Electrophysiology From Cell to Bedside, Zipes DP, Jalife Jose (Eds), W.B. Saunders, Philadelphia 2000. p.696.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/9\">",
"      Knight BP, Pelosi F, Michaud GF, et al. Physician interpretation of electrocardiographic artifact that mimics ventricular tachycardia. Am J Med 2001; 110:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/10\">",
"      Morady F, Baerman JM, DiCarlo LA Jr, et al. A prevalent misconception regarding wide-complex tachycardias. JAMA 1985; 254:2790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/11\">",
"      Baerman JM, Morady F, DiCarlo LA Jr, de Buitleir M. Differentiation of ventricular tachycardia from supraventricular tachycardia with aberration: value of the clinical history. Ann Emerg Med 1987; 16:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/12\">",
"      Ranger S, Talajic M, Lemery R, et al. Kinetics of use-dependent ventricular conduction slowing by antiarrhythmic drugs in humans. Circulation 1991; 83:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/13\">",
"      Ranger S, Talajic M, Lemery R, et al. Amplification of flecainide-induced ventricular conduction slowing by exercise. A potentially significant clinical consequence of use-dependent sodium channel blockade. Circulation 1989; 79:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/14\">",
"      Pinski SL, Trohman RG. Implantable cardioverter-defibrillators: implications for the nonelectrophysiologist. Ann Intern Med 1995; 122:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/15\">",
"      Wellens HJ, B&auml;r FW, Lie KI. The value of the electrocardiogram in the differential diagnosis of a tachycardia with a widened QRS complex. Am J Med 1978; 64:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/16\">",
"      Griffith MJ, de Belder MA, Linker NJ, et al. Multivariate analysis to simplify the differential diagnosis of broad complex tachycardia. Br Heart J 1991; 66:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/17\">",
"      Wellens HJ. Electrophysiology: Ventricular tachycardia: diagnosis of broad QRS complex tachycardia. Heart 2001; 86:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/18\">",
"      Lau EW, Pathamanathan RK, Ng GA, et al. The Bayesian approach improves the electrocardiographic diagnosis of broad complex tachycardia. Pacing Clin Electrophysiol 2000; 23:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/19\">",
"      Crijns HJ, van Gelder IC, Lie KI. Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment. Am J Cardiol 1988; 62:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/20\">",
"      Murdock CJ, Kyles AE, Yeung-Lai-Wah JA, et al. Atrial flutter in patients treated for atrial fibrillation with propafenone. Am J Cardiol 1990; 66:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/21\">",
"      Militianu A, Salacata A, Meissner MD, et al. Ventriculoatrial conduction capability and prevalence of 1:1 retrograde conduction during inducible sustained monomorphic ventricular tachycardia in 305 implantable cardioverter defibrillator recipients. Pacing Clin Electrophysiol 1997; 20:2378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/22\">",
"      Haley JH, Reeder GS. Images in cardiovascular Medicine. Wide-complex tachycardia. Circulation 2000; 102:E52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/23\">",
"      Alberca T, Almendral J, Sanz P, et al. Evaluation of the specificity of morphological electrocardiographic criteria for the differential diagnosis of wide QRS complex tachycardia in patients with intraventricular conduction defects. Circulation 1997; 96:3527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/24\">",
"      Kindwall KE, Brown J, Josephson ME. Electrocardiographic criteria for ventricular tachycardia in wide complex left bundle branch block morphology tachycardias. Am J Cardiol 1988; 61:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/25\">",
"      Rosenbaum MB. Classification of ventricular extrasystoles according to form. J Electrocardiol 1969; 2:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/26\">",
"      Swanick EJ, LaCamera F Jr, Marriott HJ. Morphologic features of right ventricular ectopic beats. Am J Cardiol 1972; 30:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/27\">",
"      Gozensky C, Thorne D. Rabbit ears: an aid in distinguishing ventricular ectopy from aberration. Heart Lung 1974; 3:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/28\">",
"      Brugada P, Brugada J, Mont L, et al. A new approach to the differential diagnosis of a regular tachycardia with a wide QRS complex. Circulation 1991; 83:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/29\">",
"      Vereckei A, Duray G, Sz&eacute;n&aacute;si G, et al. Application of a new algorithm in the differential diagnosis of wide QRS complex tachycardia. Eur Heart J 2007; 28:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/30\">",
"      Isenhour JL, Craig S, Gibbs M, et al. Wide-complex tachycardia: continued evaluation of diagnostic criteria. Acad Emerg Med 2000; 7:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/19/31034/abstract/31\">",
"      Lau EW, Ng GA. Comparison of the performance of three diagnostic algorithms for regular broad complex tachycardia in practical application. Pacing Clin Electrophysiol 2002; 25:822.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 920 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-D1AB04EF24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_19_31034=[""].join("\n");
var outline_f30_19_31034=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Diagnostic uncertainty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CAUSES OF WCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Supraventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Artifact mimicking VT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Assessment of stability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Maneuvers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Carotid sinus pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Pharmacologic interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Additional tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      EVALUATION OF THE ELECTROCARDIOGRAM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Basic features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Concordance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      AV dissociation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Dissociated P waves",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Fusion beats",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Capture beats",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      QRS morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Variation in QRS and ST-T shape",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ALGORITHMS FOR WCT DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Brugada criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Alternative approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      VT versus AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Algorithm performance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Unstable patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Stable patient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Ventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Supraventricular tachycardia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Recurrent or refractory WCT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1393749637\">",
"      Presence of a pacemaker",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Presence of an ICD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Disabling an ICD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Assessment of patient stability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Diagnosis of VT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Diagnosis of SVT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Uncertain diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      - Ventricular tachycardias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      - Supraventricular tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/920\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/920|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?24/3/24638\" title=\"algorithm 1\">",
"      Algorithm I VT versus SVT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?19/12/19662\" title=\"algorithm 2\">",
"      WCT algorithm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?39/2/39982\" title=\"algorithm 3\">",
"      Algorithm II VT versus SVT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?42/63/44022\" title=\"algorithm 4\">",
"      Adult cardiac arrest algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/920|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/58/929\" title=\"figure 1A\">",
"      Accessory AV pathways I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/19/2353\" title=\"figure 1B\">",
"      Accessory AV pathways II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/55/2929\" title=\"figure 1C\">",
"      Accessory AV pathways III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/35/15926\" title=\"figure 2\">",
"      Orthodromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/52/35655\" title=\"figure 3\">",
"      Antidromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/920|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/42/29355\" title=\"table 1\">",
"      Causes of wide QRS tach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/920|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?24/55/25464\" title=\"figure 4\">",
"      12 lead ECG antidromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?9/6/9318\" title=\"waveform 1\">",
"      ECG RMVT from LVOT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?6/4/6217\" title=\"waveform 2\">",
"      12 lead ECG orthodromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?41/16/42250\" title=\"waveform 3\">",
"      ECG atrial fibrillation in WPW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?42/59/43962\" title=\"waveform 4\">",
"      ECG with atrial fibrillation with preexcitation in WPW syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?36/31/37370\" title=\"waveform 5\">",
"      AF via multiple AV connections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?41/24/42374\" title=\"waveform 6\">",
"      Tremor artifact tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?5/61/6104\" title=\"waveform 7\">",
"      AV dissociation tutorial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?4/46/4840\" title=\"waveform 8\">",
"      Fusion beats tutorial",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/21/39256?source=related_link\">",
"      Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/13/24793?source=related_link\">",
"      Atrioventricular nodal reentrant tachycardia (junctional reciprocating tachycardia)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24311?source=related_link\">",
"      Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/26/28072?source=related_link\">",
"      Basic approach to arrhythmias due to digoxin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18308?source=related_link\">",
"      Basic approach to delayed intraventricular conduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/25/36248?source=related_link\">",
"      Basic life support (BLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/16/262?source=related_link\">",
"      Basic principles of electrocardiographic interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/56/18314?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Indications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/50/11050?source=related_link\">",
"      Cardioversion for specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/5/33882?source=related_link\">",
"      Causes and evaluation of hyperkalemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/46/35558?source=related_link\">",
"      ECG tutorial: Miscellaneous diagnoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/43/21171?source=related_link\">",
"      ECG tutorial: Preexcitation syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33719?source=related_link\">",
"      Examination of the jugular venous pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/1/3097?source=related_link\">",
"      Invasive cardiac electrophysiology studies: Tachyarrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1849?source=related_link\">",
"      Modes of cardiac pacing: Nomenclature and selection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26858?source=related_link\">",
"      Monomorphic ventricular tachycardia in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/22/361?source=related_link\">",
"      Overview of atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/49/31510?source=related_link\">",
"      Overview of cardiac pacing in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/60/13256?source=related_link\">",
"      Overview of the evaluation and management of atrial flutter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/51/27442?source=related_link\">",
"      Patient information: Ventricular tachycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/60/15305?source=related_link\">",
"      Pharmacologic therapy of arrhythmias associated with the Wolff-Parkinson-White syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/24/8585?source=related_link\">",
"      Supportive data for advanced cardiac life support in adults with sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/8/43144?source=related_link\">",
"      Sustained monomorphic ventricular tachycardia: Diagnosis and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/7/41079?source=related_link\">",
"      Treatment of acute decompensated heart failure: General considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38295?source=related_link\">",
"      Unexpected rhythms with normally functioning Dual-Chamber Pacing Systems",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_19_31035="Amount of topical medications";
var content_f30_19_31035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Amount of topical medication for adult use",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        BID/1 week",
"       </td>",
"       <td class=\"subtitle1\">",
"        TID/2 week",
"       </td>",
"       <td class=\"subtitle1\">",
"        BID/4 week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Face and neck",
"       </td>",
"       <td>",
"        15 g",
"       </td>",
"       <td>",
"        45 g",
"       </td>",
"       <td>",
"        60 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trunk",
"       </td>",
"       <td>",
"        60 g",
"       </td>",
"       <td>",
"        180 g",
"       </td>",
"       <td>",
"        240 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One arm",
"       </td>",
"       <td>",
"        15 g",
"       </td>",
"       <td>",
"        45 g",
"       </td>",
"       <td>",
"        60 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One leg",
"       </td>",
"       <td>",
"        30 g",
"       </td>",
"       <td>",
"        90 g",
"       </td>",
"       <td>",
"        120 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hands and feet",
"       </td>",
"       <td>",
"        15 g",
"       </td>",
"       <td>",
"        45 g",
"       </td>",
"       <td>",
"        60 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Body",
"       </td>",
"       <td>",
"        180 g",
"       </td>",
"       <td>",
"        0.75 to 1 kg",
"       </td>",
"       <td>",
"        1.25 to 2 kg",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    For children use one-third to one-half these amounts.",
"    <div class=\"footnotes\">",
"     BID: two times per day; TID: three times per day.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Goldstein BG, Goldstein AO, Practical Dermatology 2nd ed, Mosby-Year Book, Inc, St. Louis, MO, 1997.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_19_31035=[""].join("\n");
var outline_f30_19_31035=null;
var title_f30_19_31036="Histologic differential diagnosis of Sweet syndrome";
var content_f30_19_31036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Histologic differential diagnosis of Sweet syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Abscess/cellulitis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Positive culture for infectious agent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bowel (intestinal) bypass syndrome",
"       </td>",
"       <td>",
"        History of jejunal-ileal bypass surgery for morbid obesity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Erythema elevatum diutinum",
"       </td>",
"       <td>",
"        Erythematous asymptomatic plaques often located on the dorsal hands and elbows; younger lesions have microscopic features of leukocytoclastic vasculitis, whereas older lesions have dermal fibrosis and mucin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granuloma faciale",
"       </td>",
"       <td>",
"        Yellow to red to brown indurated asymptomatic facial plaques; there is a grenz zone of normal papillary dermis beneath which there is a dense diffuse inflammatory infiltrate of predominantly neutrophils (with microscopic features of leukocytoclastic vasculitis) and frequently numerous eosinophils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Halogenoderma",
"       </td>",
"       <td>",
"        Neutrophilic dermal infiltrate with necrosis and pseudoepitheliomatous hyperplasia with intraepidermal abscesses; history of ingestion of bromides (leg lesions), iodides (facial lesions), or topical fluoride gel to teeth during tumor radiation therapy to face",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukemia cutis",
"       </td>",
"       <td>",
"        Dermal infiltrate consists of immature neutrophils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukocytoclastic vasculitis",
"       </td>",
"       <td>",
"        Vessel wall destruction - extravasated erythrocytes, fibrinoid necrosis of vessel walls, karyorrhexis, and neutrophils in the vessel wall",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lobular neutrophilic panniculitides",
"       </td>",
"       <td>",
"        In addition to subcutaneous Sweet syndrome, these include alpha 1-antitrypsin deficiency syndrome, factitial panniculitis (secondary to the presence of iatrogenic or self-induced foreign bodies), infectious panniculitis (secondary to either a bacterial, fungal, mycobacterial, or protozoan organism), pancreatic panniculitis, rheumatoid arthritis-associated panniculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neutrophilic eccrine hidradenitis",
"       </td>",
"       <td>",
"        Neutrophils around eccrine glands, often in patients with acute myelogenous leukemia receiving induction chemotherapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyoderma gangrenosum",
"       </td>",
"       <td>",
"        Painful ulcer with overhanging, undermined violaceous edges",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid neutrophilic dermatitis",
"       </td>",
"       <td>",
"        History of rheumatoid arthritis, nodules, and plaques",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sweet's syndrome",
"       </td>",
"       <td>",
"        Acute onset, fever, neutrophilia, and painful plaques",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Cohen PR. Paraneoplastic dermatopathology: cutaneous paraneoplastic syndromes. Adv Dermatol 1995; 11:215. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_19_31036=[""].join("\n");
var outline_f30_19_31036=null;
var title_f30_19_31037="ASGE guidelines Abx prophylxs";
var content_f30_19_31037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antibiotic prophylaxis for endoscopic procedures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Patient condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Procedure contemplated",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antibiotic prophylaxis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        High risk:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" rowspan=\"2\">",
"        <p>",
"         Prosthetic heart valve or prosthetic material used for valve repair",
"        </p>",
"        <p>",
"         History of endocarditis",
"        </p>",
"        <p>",
"         Unrepaired cyanotic congenital heart disease (including palliative shunts and conduits)",
"        </p>",
"        <p>",
"         Repaired congential heart disease with residual defects at the site of or adjacent to a prosthetic device",
"        </p>",
"        <p>",
"         Completely repaired congenital heart defects with prosthetic material or device during the first six months after the repair",
"        </p>",
"        <p>",
"         Cardiac valvulopathy in a transplanted heart",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\">",
"        <p>",
"         Stricture dilation",
"        </p>",
"        <p>",
"         Variceal sclerotherapy",
"        </p>",
"        <p>",
"         ERCP/obstructed biliary tree",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Not recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Other endoscopic procedures, including EGD and colonoscopy (with or without biopsy/polypectomy), variceal ligation",
"       </td>",
"       <td class=\"sublist_other\">",
"        Not recommended",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Moderate risk:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" rowspan=\"2\">",
"        <p>",
"         Most other congenital abnormalities",
"        </p>",
"        <p>",
"         Acquired valvular dysfunction (eg, rheumatic heart disease)",
"        </p>",
"        <p>",
"         Hypertrophic cardiomyopathy",
"        </p>",
"        <p>",
"         Mitral valve prolapse with regurgitation or thickened leaflets",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\">",
"        <p>",
"         Esophageal stricture dilation",
"        </p>",
"        <p>",
"         Variceal sclerotherapy",
"        </p>",
"       </td>",
"       <td class=\"sublist_other\">",
"        Not recommended",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        Other endoscopic procedures, including EGD and colonoscopy (with or without biopsy/polypectomy), variceal ligation",
"       </td>",
"       <td class=\"sublist_other\">",
"        Not recommended",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Low risk:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Other cardiac conditions (CABG, repaired septal defect or patent ductus, mitral valve prolapse without valvular regurgitation, isolated secundum atrial septal defect, physiologic/functional/innocent heart murmurs, rheumatic fever without valvular dysfunction, pacemakers, implantable defibrillators)",
"       </td>",
"       <td class=\"sublist_other\">",
"        All endoscopic procedures",
"       </td>",
"       <td class=\"sublist_other\">",
"        Not recommended",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Obstructed bile duct without cholangitis",
"       </td>",
"       <td>",
"        ERCP with complete drainage",
"       </td>",
"       <td>",
"        Not recommended",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Obstructed bile duct with cholangitis",
"       </td>",
"       <td>",
"        ERCP with anticipated incomplete drainage",
"       </td>",
"       <td>",
"        Recommended (continue antibiotics after procedure)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Pancreatic cystic lesion",
"       </td>",
"       <td>",
"        ERCP, EUS-FNA",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Cirrhosis acute gastrointestinal bleed (required for patients with or without endoscopic procedures)",
"       </td>",
"       <td>",
"        All endoscopic procedures",
"       </td>",
"       <td>",
"        Recommended",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Ascites, immunocompromised patient",
"       </td>",
"       <td>",
"        <p>",
"         Stricture dilation",
"        </p>",
"        <p>",
"         Variceal sclerotherapy",
"        </p>",
"        <p>",
"         Other endoscopic procedures, including EGD and colonoscopy (with or without biopsy/polypectomy), variceal ligation",
"        </p>",
"       </td>",
"       <td>",
"        No recommendation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        All patients",
"       </td>",
"       <td>",
"        Percutaneous endoscopic feeding tube placement",
"       </td>",
"       <td>",
"        Recommended (parenteral cephalosporin or equivalent)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Vascular graft",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         AHA: Recommended antibiotic usage within 6 months of procedure",
"        </p>",
"        <p>",
"         ASGE: Antibiotics not recommended",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Prosthetic joints",
"       </td>",
"       <td>",
"        All endoscopic procedures",
"       </td>",
"       <td>",
"        Not recommended",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    This summary table is based upon recommendations from the American Society of Gastrointestinal Endoscopy (Banerjee, S, Shen, B, Baron, T, et al. Gastrointest Endosc 2008; 67:791) and the American Heart Association (Wilson, W, Taubert, KA, Gewitz, M, et al. Circulation 2007; 116:1736 and Nishimura, RA, Carabello, BA, Faxon, DP, et al. Circulation 2008; 118:887). NOTE: See other table (\"Antibiotic regimens: Prophylaxis for endoscopic procedures\") for specific regimens.",
"    <div class=\"footnotes\">",
"     CABG: coronary artery bypass graft; ERCP: endoscopic retrograde cholangiopancreatography; EGD: esophagogastroduodenoscopy; EUS-FNA: endoscopic ultrasound with fine needle aspiration; AHA: American Heart Association; ASGE: American Society for Gastrointestinal Endoscopy.",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Hirota WK, Petersen K, Baron TH, et al. Guidelines for Antibiotic Prophylaxis for GI Endoscopy. Gastrointest Endosc 2003; 58:475. Copyright &copy; 2003 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_19_31037=[""].join("\n");
var outline_f30_19_31037=null;
var title_f30_19_31038="NBO versus HBO algorithm";
var content_f30_19_31038=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59259&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Algorithm for using normobaric and hyperbaric oxygen following carbon monoxide exposure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 321px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CO: carbon monoxide; ECG: electrocardiogram; CO-Hgb: carboxyhemoglobin; NBO: normobaric oxygen; HBO: hyperbaric oxygen; N/V: nausea and vomiting.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: O'Brien C, Manaker S. Carbon monoxide and smoke inhalation. The Intensive Care Manual. Hanson, Lanken, Manaker (Eds), WB Saunders, Philadelphia, 2001.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_19_31038=[""].join("\n");
var outline_f30_19_31038=null;
var title_f30_19_31039="Aphthoid ulcers Crohns BE";
var content_f30_19_31039=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aphthoid ulcers in Crohn's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 284px; height: 353px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Double contrast barium enema demonstrates small aphthoid ulcers in a patient with early Crohn's disease of the colon (arrows). Barium has collected in the superficial erosions, which are surrounded by edematous mucosa. These small erosions, less typically seen in ulcerative colitis, are the precursors of larger discrete ulcers, fistulae, and sinus tracts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_19_31039=[""].join("\n");
var outline_f30_19_31039=null;
